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Preface
The work described in this thesis was done in collaboration with members of the
Engelward and So laboratories. The Fluorescent Yellow Direct Repeat mice were created
by Carrie A. Hendricks, Karen H. Almeida, Molly S. Stitt and others from the Engelward
laboratory. I am extremely grateful to all those who contributed to this thesis project.
Chapter II was published in PNAS in August of 2006. The development of the
assay for analyzing recombinant cells by flow cytometry and the collection of data for the
analysis of recombinant cell type data was done in collaboration with Carrie A.
Hendricks. Werner Olipitz, Carrie A. Hendricks and the author collected the data for the
distribution of spontaneous recombinant cell frequencies in pancreatic tissue. Arlin B.
Rogers performed the histological analysis to determine recombinant pancreatic cell type.
The collection of data for the effect of mitomycin-C and age on homologous
recombination was done in collaboration with Werner Olipitz. All other results and
assays were contributed by the author.
Chapter III was published in Cell Cycle in December of 2006. Initial
characterization of positive control FYDR-Recombined mice was done in collaboration
with Carrie A. Hendricks. Werner Olipitz was instrumental in helping to collect data for
the effect of mitomycin-C treatment on homologous recombination. Histological analysis
of positive control FYDR-Recombined tissue sections was done by Arlin B. Rogers. All
other results and assays were contributed by the author.
In Chapter IV, epifluorescence and two-photon microscopy techniques were
developed in the laboratory of Peter T. So by Hyuk-Sang Kwon. Data for the number of
cells per recombinant focus were collected by Yoon Sung Nam and Hyuk-Sang Kwon.
Image analysis for quantification of cells per recombinant foci was done by Hyuk-Sang
Kwon. The author contributed all other work.
In Chapter V, Carrie A. Hendricks developed the assays for detection of
recombinant skin cells by flow cytometry. Werner Olipitz, Carrie A. Hendricks and the
author collected the data for the distribution of spontaneous recombinant cell frequencies
in skin and pancreas and for the frequency of recombinant skin cells with age. The assay
for determining the effect of mitomycin-C on homologous recombination in vitro was
developed in collaboration with Carrie A. Hendricks. The protocol used to measure the
rate of homologous recombination was modified from an assay developed by Carrie A.
Hendricks. Analysis of DNA damage by the Comet assay was done by Werner Olipitz.
The sister chromatid exchange analysis was done in collaboration with Rebecca E. Rugo.
The author contributed all other work.
Chapter VI will be submitted as a manuscript pending data collection for the
effect of p53 status on DNA damage induced recombination. Data for the frequency of
recombinant cells, the number of recombinant foci and the rate of homologous
recombination was collected in collaboration with Saja A. FakhralDeen. The author was
primarily responsible for all other work.
Acknowledgements
With great sincerity and gratitude, I would like to thank my advisor Professor
Bevin P. Engelward. While teaching me the scientific process, Bevin has been a mentor
both scientifically and personally with her constant patience and guidance. She has set
high scientific standards, created opportunities for me to develop and challenged me to
perform. I have especially appreciated Bevin's enthusiasm for solving problems. She
inspires her students to think big, with creative and far reaching solutions to answer
problems both locally for their own research and globally for the environmental health
issues facing the world.
I would also like to thank all of the current and former members of the Engelward
Laboratory. Their advice, support, friendship and especially their cheerful nature created
an environment within which it was a pleasure to work! I would especially like to thank
Carrie A. Hendricks who patiently passed to me a tremendous wealth of intellectual and
technical knowledge that enabled me to be successful from the first day I joined the lab.
In addition, I would like to thank Werner Olipitz, who even after endless hours of mouse
work, imaging, flow cytometry and tissue culture was always ready with a joke and a
smile. I am very grateful to Saja A. FakhralDeen for her careful work, dedication and
desire to learn. I would like to thank Yoon Sung Nam whose persistence on the two-
photon project enabled its ulimate success. Also, I would like to extend a special thanks
to Rebecca E. Rugo and James T. Mutamba, who were always willing to discuss data,
provide helpful suggestions and make the lab such a pleasant place to be.
It is with gratitude and respect that I would like to acknowledge my thesis
committee members, Profs. David Schauer, John Essigmann and Leona Samsom for their
insight, guidance and support during my graduate work. Thank you to the members of the
Peter So Laboratory, especially Hyuk-Sang Kwon, for their work on creating the two-
photon imaging technique. Also, many thanks to the staff of the M.I.T Flow Cytometry
Facility and the M.I.T. Department of Comparative Medicine, especially Glenn Paradis,
Dr. Arlin Rogers, Kathleen Cormier, Dr. Susan Erdman, Elizabeth Horrigan, and
Stephanie Haskell.
Finally, I would like to especially thank my loving family. I am forever grateful to
my parents for teaching me kindness, honesty and independence, for instilling me with
the confidence to succeed and to fail, for encouraging me to follow my dreams and for
providing me with every opportunity to do so. I am grateful to my sister for her humor,
understanding, encouragement and selflessness. I would also like to thank my
grandparents who have taught me to be proud and shown me the true meaning of success.
Most of all, I would like to thank my wonderful husband, Justin for his love, friendship,
encouragement and endless support as I follow my dreams. His unselfish attitude and
outlook on life has made all of this possible!
The Impact of Age, Exposure and Genetics on Homologous
Recombination at an Engineered Repeat Sequence in Mice
by
Dominika M. Wiktor-Brown
Submitted to the Division of Biological Engineering on May 24, 2007 in partial
fulfillment of the requirements for the Degree of Doctor of Philosophy in Applied
Biosciences
Abstract
Mitotic homologous recombination is a critical pathway for the repair of DNA
double-strand breaks and broken replication forks. Although homologous recombination
is generally error-free, recombination between misaligned sequences can lead to
deleterious sequence rearrangements, and conditions that stimulate homologous
recombination are associated with an increased risk of cancer. To study homologous
recombination in vivo, we used Fluorescent Yellow Direct Repeat (FYDR) mice in which
a homologous recombination event at a transgene yields a fluorescent cell. To study
homologous recombination using FYDR mice, we developed one- and two-photon in situ
imaging techniques that reveal both the frequency and the sizes of isolated recombinant
cell clusters within intact pancreatic tissue. We then applied these tools to analyze the
effects of cancer risk factors such as exposure, genetic predisposition and age on
homologous recombination in vivo.
To determine the effect of exposure to exogenous carcinogens on homologous
recombination, FYDR mice were treated with two different chemotherapeutic agents,
cisplatin and mitomycin-C. Results show that exposure to these DNA damaging agents
causes an induction of recombinant pancreatic cells in vivo, indicating that homologous
recombination is an active repair pathway in adult pancreatic cells and that exposure to
certain carcinogens stimulates recombinational repair.
As a first step towards exploring the effect of genetic predisposition to genomic
instability on homologous recombination in vivo, FYDR mice were crossed with mice
carrying a defect in p53, a critical tumor suppressor that is mutated in almost 50% of all
human tumors. Although loss of p53 is known to promote genomic instability, results
show that p53 status does not significantly affect the spontaneous recombinant cell
frequency in the pancreas in vivo or the rate of homologous recombination in cultured
fibroblasts in vitro.
Age is a risk factor for many types of cancers. Here we examined the effect of age
on homologous recombination in two tissues of FYDR mice, pancreas and skin. In the
pancreas, a dramatic accumulation of recombinant cells is seen with age, resulting from
both de novo recombination events and clonal expansion of recombinant cells. In contrast,
the skin shows no increase in recombinant cell frequency with age. In vitro studies using
primary fibroblasts indicate that the ability to undergo homologous recombination in
response to endogenous and exogenous DNA damage does not significantly change with
age, suggesting that these skin cells are able to undergo de novo homologous
recombination events in aged mice. Thus, we propose that tissue-specific differences in
the accumulation of recombinant cells with age result from differences in the ability of
these cells to persist and clonally expand within the tissue.
To further characterize the FYDR mice as a tool for studying homologous
recombination, we exploited positive control FYDR-Recombined mice in which all cells
carry the full-length coding sequence for enhanced yellow fluorescent protein. Studies
show that expression of the FYDR transgene varies among mice, among tissues, and even
among cells within a tissue. However, the variation in FYDR expression does not
significantly change with age or exposure to exogenous carcinogens. Furthermore,
positive control mice reveal that several tissues, in addition to the pancreas and skin, may
be amenable for studying homologous recombination in the FYDR mice. Thus, our
studies demonstrate that FYDR mice combined with in situ imaging technology provide
powerful tools to study the effects of cancer risk factors on homologous recombination in
vivo. Ultimately, by applying these techniques to study additional cancer risk factors, we
may better understand the relationship between DNA damage, homologous
recombination and cancer.
Thesis Supervisor: Bevin P. Engelward
Title: Associate Professor of Biological Engineering
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Chapter I
Introduction
Chapter 1
1.1 Homologous Recombination and Genomic Stability
Mitotic homologous recombination is critical for the repair of genome
destabilizing DNA damage, such as double-strand breaks and interstrand cross-links.
These DNA lesions can be caused by environmental exposures, such as radiation or
chemotherapy, and by endogenous cellular metabolites, such as reactive oxygen species
(1-4). In addition, double-strand breaks can occur as the result of DNA processing. For
example, replication fork encounter with a DNA lesion or a single strand gap can cause
replication fork breakdown, creating a double strand end (5-9) (Figure 1-1). Regardless of
how they arise, double-strand breaks are considered to be among the most cytoxic and
mutagenic DNA lesions, since a single unrepaired double-strand break can result in the
permanent loss of over 100 million base pairs of genetic information (10), and misjoining
of double-strand breaks can lead to gross chromosomal rearrangements (11). By using
homologous DNA sequences present on the sister chromatid or homologous chromosome
as templates, homologous recombination can repair double-strand breaks with high
fidelity (Figure 1-2A). In addition, homologous recombination provides the only pathway
for the accurate repair of double-strand breaks that arise as a result of broken replication
forks (12). Thus, homologous recombination is important for preventing mutagenic
sequence rearrangements that can result from double-strand breaks.
In addition to homologous recombination, cells use another DNA repair pathway,
nonhomologous end-joining, to recognize and repair double-strand breaks. In contrast to
homologous recombination which uses homologous sequences as templates for repair,
nonhomologous end-joining directly rejoins double-strand breaks, regardless of sequence
(13, 14) (Figure 1-2B). Nonhomologous end-joining is the preferred pathway for the
repair of double-strand breaks during Go/G 1 phases of the cell cycle, whereas homologous
recombination is important during late S/G 2 (15). Although homologous recombination is
generally error free, exchanges between misaligned sequences can lead to insertions,
deletions, translocations, and loss of heterozygosity. Since over 40% of the genome is
comprised of repeated elements (16), high levels of homologous recombination during
Go/G 1 can lead to increased recombination between misaligned sequences. Thus,
nonhomologous end-joining is preferred during Go/G 1 to minimize deleterious
rearrangements (17). In contrast, when a sister chromatid is present during S phase,
homologous recombination is preferred since it plays an essential role in the repair of
double-strand breaks at broken replication forks (12). If replication fork-associated
double-strand breaks are instead acted upon by nonhomologous end-joining, ends from
independent loci can be joined, which will inevitably lead to large scale sequence
rearrangements. Therefore, in order to prevent mutation formation, it is critical that cells
initiate the appropriate double-strand break repair pathway.
Given its key role in the repair of double-strand breaks and broken replication
forks, it is not surprising that loss of function of homologous recombination can promote
genomic instability. Germline deletions of key homologous recombination proteins are
embryonic lethal in mice (e.g., RAD51 (18-21), BRCA1 (22), BRCA2 (22, 23)). In
addition, inherited mutations in genes that result in impaired homologous recombination
function are associated with higher incidences of cancer. For example, germline
mutations in BRCA], BRCA2, FANCC, and NBS1 increase the risk of many types of
cancer (24-28). Loss of function of these genes suppresses homologous recombination
(29-32) and causes an increased frequency of tumor-promoting sequence rearrangements
(33, 34).
While the suppression of homologous recombination can cause genomic
instability, too much homologous recombination can also increase the risk of deleterious
sequence rearrangements. The repair of a double-strand break by homologous
recombination requires a repair template, i.e., a sequence of duplex DNA that is
homologous to the sequence surrounding the double-strand break. A sister chromatid,
homologous chromosome or one of many repeated elements throughout the genome (16)
can all potentially serve as repair templates for a double-strand break. Recombinational
repair involves the nonreciprocal transfer of genetic sequence information from a donor
template to the broken strand, a process known as gene conversion. In addition, the
resolution of homologous recombination intermediates can lead to exchanges of flanking
sequences. Thus, an inherent risk of deleterious sequence changes is associated with
every homologous recombination event and depends upon which substrate is chosen as
the repair template. For example, a sister chromatid carries genetic information identical
to that of the broken strand; thus, the chance of deleterious sequence rearrangements is
minimal. In contrast, transferring genetic information or exchanging flanking sequences
from a homologous chromosome or repeated element can lead to mutations such as loss
of heterozygosity and translocations, sequence changes that can initiate or promote
cancer (35). Thus, increased levels of homologous recombination increase the likelihood
of potentially deleterious gene conversion events.
Given that increased levels of homologous recombination can promote genomic
instability, it is not surprising that germline mutations in genes that increase homologous
recombination are associated with higher cancer incidence and often with an accelerated
aging phenotype. For example, inherited mutations in two RecQ-like DNA helicases,
WRN and BLM, cause Werner and Bloom syndromes, respectively (36-38). Both
syndromes are characterized by increased cancer risk (24), and Werner syndrome patients
also exhibit an accelerated aging phenotype (39). WRN and BLM are believed to play
important roles in the resolution of homologous recombination intermediates, particularly
those that arise at stalled replication forks (40-44), and loss of function of either WRN or
BLM is associated with an increased frequency of deleterious recombination events (45-
49). In addition to BLM and WRN, heritable mutations in ATM (ataxia-telangiectasia,
mutated), a protein that plays a critical role in initiating double-strand break repair (50),
result in ataxia telangiectasia, a disease that is associated with increased cancer incidence
and symptoms of premature aging (51, 52). Interestingly, ATM-' cells show an increased
frequency of homologous recombination and are particularly susceptible to error-prone
homologous recombination (53-56). Taken together, these data suggest that deregulation
of homologous recombination can promote sequence rearrangements that cause genomic
instability.
1.2 Recognition and Repair of Double Strand Breaks by Homologous
Recombination
The repair of a double-strand break occurs via a series of complex signaling
cascades that are initiated by the recognition of the double-strand break. Although the
exact mechanism of double-strand break recognition is not known, one of the earliest
repair factors present at the site of a double-strand break is the Mrel -Rad50O-Nbs 1
(MRN) complex, which recruits and activates ATM (57-61). Subsequently, activated
ATM serves as a key facilitator of the double-strand break repair signaling cascade (for a
review see (50)) as it phosphorylates a number of downstream targets, such as p53 (62-
64), MDM2 (65, 66), CHK2 (67, 68), BRCA1 (69-71), and NBS1 (72-75). Importantly,
loss of function of many of these proteins involved in the recognition of double-strand
breaks results in impaired double-strand break repair and increased genomic instability
(28, 50).
Once a double-strand break has been recognized, repair of the double-strand break
by homologous recombination is initiated by the MRN complex, which contributes to the
5' to 3' resection of the double-strand ends to produce the single-stranded 3' overhang
required for homologous recombination (76) (Figure 1-3A, 1). NBS1 of the MRN
complex contains binding domains that recruit the complex to the double-strand break
(77), RAD50 has long coiled coils that hold adjacent strands of DNA together (78-80),
and MRE11 has associated nuclease activity that is believed to contribute to the
processing of the double-strand break ends (81, 82). Once a single-stranded 3' overhang
is formed, it is protected from further nuclease activity by coating with the single-strand
binding protein RPA.
In addition to ATM and MRN, another complex of proteins, the Fanconi Anemia
complex (FANCA, C, E, F, G, L), is activated in response to DNA damage and aids in
the initiation of the next step of homologous recombination, the loading of RAD51 onto
the 3' overhangs (83-85). The activated Fanconi Anemia complex promotes the loading
of BRCA2 onto the ends of the double-strand break (86, 87). Subsequently, BRCA2
displaces RPA from the single-stranded 3' ends and initiates the formation of the RAD51
nucleoprotein filament (88). The RAD51 nucleoprotein filament facilitates homology
searching, invasion into duplex DNA, and strand exchange (Figure 1-3A, 2) (89). In
addition to RAD51, many proteins including RAD52, RAD54, and the RAD51 paralogs
(RAD5 lb, RAD51 c, RAD51 d, XRCC2, and XRCC3) stimulate homologous
recombination, although their exact functions have not yet been elucidated (2).
Once a homologous sequence is located, DNA synthesis using the duplex DNA as
a template is initiated to extend the 3' end of the invading strand beyond the original
break site, restoring any missing sequence information at the double-strand break (Figure
1-3A, 3). The process of invasion and strand synthesis leads to the formation of a four-
branched structure called a Holliday Junction (Figure 1-3A, 4). The steps described above
(i.e., 5' to 3' resection of the double-strand end to produce a 3' overhang, formation of a
RAD51 nucleoprotein filament, homology searching, strand invasion, strand exchange,
synthesis and Holliday Junction formation) are common to all homologous recombination
events. However, the resolution of the Holliday Junction differs between proposed
models of homologous recombination.
The predominant mechanism by which homologous recombination repairs two-
ended double-strand breaks is believed to be Synthesis-Dependent Strand Annealing
(SDSA) (12). In the Synthesis-Dependent Strand Annealing model, the Holliday Junction
can move along the DNA via branch migration (90) (Figure 1-3A, 5), which is believed
to be facilitated by a number of proteins including BLM, WRN, and RAD54 (41, 43, 91).
Branch migration of the Holliday Junction in the direction of DNA synthesis can result in
release of the invading DNA strand from the duplex DNA (Figure 1-3A, 6). The invasion
and synthesis steps can occur independently for both ends of the double-strand break. If
DNA synthesis of at least one invading strand extends past the break point, the two ends
of the double-strand break will contain complementary sequences that can be used to
anneal the two double-strand ends together (Figure 1-3A, 6), thus repairing the double-
strand break with transfer of genetic sequence from the donor template to the site of the
double-strand break.
Although Synthesis-Dependent Strand Annealing is thought to be the prevalent
mechanism of double-strand break repair by homologous recombination, a second type of
repair, Double-Strand Break Repair (DSBR), can occur if branch migration does not
release the invading strand (92, 93). In this case, in order to separate the two DNA
duplexes, the Holliday Junctions formed from both ends of the double-strand break must
instead be cleaved (Figure 1-3B, 4). Depending on how these junctions are cleaved,
flanking sequences may or may not be exchanged between the two DNA duplexes
(crossover or non-crossover, respectively) (Figure 1-3B, 5). To note, analysis of
resolution products from the repair of site-specific double-strand breaks by homologous
recombination shows that crossover events are rare. Instead, gene conversion events
without crossover are the predominant outcome (94), suggesting that the Double-Strand
Break Repair model may not be the predominant mechanism by which most
recombinational repair of double-strand breaks occurs in vivo.
While two-ended double-strand breaks can be repaired by either nonhomologous
end-joining or homologous recombination, the accurate repair of one-ended double-
strand breaks created at broken replication forks can only be accomplished by
homologous recombination (12). When a replication fork encounters a single-strand nick
or gap in the DNA backbone (or a lesion that it cannot bypass), the replication fork
breaks down and a double stranded end is released (Figure 1-1) (5-9, 95). In a process
called break induced replication (BIR), homologous recombination uses homologous
sequences present in the sister chromatid to reinsert the broken end into the DNA duplex
to restore the broken replication fork (12). During break induced replication, reinsertion
of the double stranded end proceeds by a mechanism that is essentially a one-ended
invasion process analogous to Synthesis-Dependent Strand Annealing, i.e., 5' to 3'
resection to produce a 3' overhang, homology searching, strand invasion, strand
exchange, synthesis and Holliday Junction formation (Figure 1-3C, 1-2). The Holliday
Junction formed by the invading and template strands must be cleaved in order to resolve
the two DNA duplexes (Figure 1-3C, 3) and restart the replication fork (Figure 1-3C, 4).
Thus, homologous recombination provides the only pathway to accurately repair
replication fork-associated double-strand breaks.
1.3 Using Fluorescent Yellow Direct Repeat Mice to Study
Homologous Recombination in vivo
A number of mouse models have previously been used to detect mitotic
homologous recombination events that occur in vivo, including pink-eyed unstable (pn),
Aprt, - and Tkh- mice. pu" mice carry a naturally occurring 70 kb duplication at the p
locus, a gene responsible for normal melanin production (96-98). The duplication
prevents normal melanin expression, resulting in mice with light gray fur and pink eyes.
A homologous recombination event early during embryonic development that deletes one
of the 70 kb duplications can restore normal p gene function and give rise to black spots
on the gray fur and retinal epithelium of adult mice (96, 99, 100). pun mice have been
used extensively to study the effect of environmental agents and genetic conditions on
homologous recombination (101-107). However, because clonal expansion of
recombined cells is required to detect spots on both fur and retinal epithelium, pun mice
can only be used to study recombination events that occur during embryogenesis, and
information about the repair of DNA lesions by homologous recombination in adult
tissues cannot be gathered.
In contrast to the naturally occurring recombination substrate present in pun mice,
Aprt+/ and Tk'- mice have been engineering to measure homologous recombination
events indirectly by assessing loss of heterozygosity (108-111). In these mice, loss of
heterozygosity events leading to loss of function of Aprt or Tk result in cells that exhibit
a selectable phenotype. Although loss of heterozygosity can be caused by many different
mechanisms, it has been shown that a significant fraction of the gene loss in Aprt÷- mice
is due to mitotic recombination events (110, 112-114). Thus, these mouse models have
been used to indirectly measure the effects of age, environment, and genetics on
homologous recombination (115-122). However, since cells must be cultured in the
presence of toxic base analogs in order to detect loss of heterozygosity events, these mice
can only be applied to study homologous recombination in cells that can be cultured ex
vivo.
Given the limitations of these mouse models for the detection of homologous
recombination events that occur in vivo, little was known about homologous
recombination in many adult somatic tissues until the development of the Fluorescent
Yellow Direct-Repeat (FYDR) mice (123), which enabled studies of homologous
recombination in adult somatic cells. The FYDR mouse carries two truncated copies of
the expression cassette for the enhanced yellow fluorescent protein (EYFP) arranged in
tandem (Figure 1-4). The 3' eyfp cassette lacks the first 96 bp of coding sequence from
the N-terminus, and the 5' eyfp lacks the final 42 bp from the C-terminus of the EYFP
coding sequence. The truncation of essential coding sequences prevents expression of
EYFP. A homologous recombination event between the two cassettes can restore the full
length EYFP coding sequence, thus yielding a fluorescent cell. One advantage of using
fluorescence as a marker for sequence changes is that cells harboring recombined DNA
can potentially be detected within intact tissues. Thus, the FYDR mice can be applied to
reveal the effects age, genetics, and exposure on homologous recombination in adult
somatic tissues in vivo.
1.4 Pancreas and Pancreatic Cancer
Pancreas Anatomy and Physiology
Inherited mutations in proteins that modulate homologous recombination (i.e.,
BRCAl, BRCA2, and FANCC) increase the risk of pancreatic cancer (24-26, 29-32).
Although these findings suggest that homologous recombination is critical for
maintaining genomic integrity in the pancreas, no studies had explored the activity of
homologous recombination in mature pancreatic cells.
The pancreas is located posteriorly in the upper abdomen, attached to the
duodenum and can be divided histologically into two parts, the exocrine and endocrine
pancreas (124) (Figure 1-5). The exocrine pancreas makes up approximately 95% of the
volume of the organ and consists of two main cell types, acinar (85%) and ductal
epithelial (10%) cells (125). The secretory unit within the exocrine pancreas is a grape-
like structure called an acinus, which contains ten to forty acinar cells that secrete
enzymes into a system of epithelial ducts (126).The epithelial ducts carry these hydrolytic
enzymes, such as trypsin, chemotrypsin, elastase, and amylases, into the duodenum
where they aid in digestion (125).
The endocrine pancreas makes up the remaining 5% of the volume of the organ
and consists of islets of Langerhans interspersed throughout the pancreas (Figure 1-5).
Islets contain four major cell types: P (beta), a (alpha), 6 (delta), and PP cells. The 3 cells
(60-80% of the endocrine pancreas) secrete insulin, a cells (15-20% of the endocrine
pancreas) secrete glucagon, 8 cells (5-10% of the endocrine pancreas) produce
somatostatin, and PP (< 2% of the endocrine pancreas) cells secrete a pancreatic
polypeptide that stimulates secretion of gastric and intestinal enzymes (127).
Although the development and function of pancreatic cells has been studied
extensively, the identification of an adult pancreatic stem cell within either the exocrine
or endocrine pancreas has eluded scientists (128, 129). Data shows that in the adult
pancreas, both cellular compartments of the pancreas proliferate, although at low levels
(-1% of cells are in S phase (130)). In addition, pancreatic cells persist for long periods
of time (131, 132), with half-lives estimated to be -70-132 days for acinar cells, -40 days
for ductal cells, and -47-170 days for islet cells (133, 134). Although pancreatic cells are
normally quiescent, in response to damage, such as pancreatectomy or chemical injury,
proliferation of acinar, ductal, and islet cells is stimulated (135-137). Since homologous
recombination is most active during S phase of the cell cycle (94) and since pancreatic
cells normally exhibit low proliferation rates, the importance of homologous
recombination on mutant cell frequency in the pancreas may only be revealed after long
periods of time, for example, in pancreata of aged mice. By labeling recombinant cells
with fluorescence, the FYDR mice enable the analysis of the cumulative effects of
homologous recombination in pancreatic cells over time, thus potentially revealling the
role of homologous recombination in tissues with low proliferation rates such as the
pancreas.
Pancreatic Cancer
With a 5 year survival rate of less than 5%, pancreatic cancer remains one of the
deadliest cancers in the United States (138, 139). The majority of pancreatic neoplasms
are ductal pancreatic adenocarcinomas (80-90%). Although most pancreatic tumors
appear to have a ductal phenotype, there is debate over the actual origin of cells that
appear in ductal andenocarcinomas. Some studies suggest that acinar cells are able to
transdifferentiate to acquire the features of ductal cells. For example, multiple in vitro
studies have been able to show transdifferentiation of primary acinar cells to ductal cells
(140-144). In addition, in vivo studies show that mice expressing oncogenic K-ras or
TGF-a targeted specifically to the acinar cell compartment developed pancreatic
intraepithelial neoplasias and pancreatic ductal adenocarcinoma (145-150). Interestingly,
expression of oncogenic K-ras under promoter specific for pancreatic ductal epithelial
cells does not result in the development of neoplastic lesions (151). Together, these data
suggest that acinar cells may play an important role in tumor formation.
Pancreatic cancer, like most other cancers, results from the accumulation of
multiple genetic mutations. Over the last several years, mutations in specific tumor-
suppressor and oncogenes (i.e., KRAS, CDKN2A/pl6, p53, SMAD4/DPC4, HER2/neu,
and BRCA2) have been identified for progressive stages of pancreatic cancer, with more
severe cancers exhibiting accumulation of mutations in multiple genes (139, 152). The
underlying causes of changes in the expression of many of these genes have been
analyzed and include translocations, amplifications, deletions, point mutations, and loss
of heterozygosity (139). Given the importance of homologous recombination proteins
both in the predisposition to (i.e., inherited mutations in BRCA1, BRCA2, FANCC) and in
the progression of pancreatic cancer, determining the effect of cancer risk factors on
homologous recombination in pancreatic cells may be important to understanding the
mechanisms of cellular transformation in the pancreas, and the FYDR mice provide a
unique tool for assessing the effect of these risk factors on homologous recombination in
vivo.
1.5 Skin and Wound Healing
Skin Anatomy and Physiology
A number of studies have analyzed homologous recombination in skin cells in
vivo. As mentioned above, pun mice, in which the clonal expansion of embryonic
recombination events appear as dark spots on the light gray skin, have been used to study
the effects of multiple genetic and environmental factors on homologous recombination
in skin cells (101-107). However, since this assay is limited to measuring recombination
events that occur during embryogenesis, homologous recombination in adult skin cannot
be analyzed. Using Aprt - mice, one study determined the effect of age on homologous
recombination in ear fibroblasts and observed a small increase in the frequency of loss of
heterozygosity events with age in cells from female mice (117). However, in order to
determine mutant cell frequency in Aprt+- mice, cells have to be cultured in the presence
of a base analog ex vivo; thus, mutation events that occur in vitro versus in vivo cannot be
differentiated. Therefore, although some studies have analyzed homologous
recombination in the skin, little is known about the in vivo frequency of recombinant cells
in adult skin.
The skin forms the largest organ of the body and performs vital roles both as a
barrier against microorganisms and chemical insults and as a regulator of heat and water
loss from the body. The skin can be divided histologically into 3 distinct layers: the
epidermis, dermis, and subcutaneous tissue (Figure 1-6). The epidermis is the outermost
layer of skin, composed mostly of keratinocytes, with interspersed antigen presenting
cells and pigment producing melanocytes. The keratinocytes located within the basal
layer of the epidermis actively proliferate, giving rise to cells that differentiate as they
move upward through the suprabasal layers until being shed at the surface of the skin
(153), a process that takes -10-14 days in the mouse skin (154). The next layer of skin
just below the epidermis is the dermis. The main cell type located within the dermis is the
fibroblast which secretes collagen, elastin and other proteins and cytokines into the
extracellular matrix. In addition, the dermis contains immune cells and other cellular
structures such as hair follicles, sebaceous glands, sweat glands, nerves and blood vessels.
Finally, the innermost layer of the skin is the subcutaneous layer which contains adipose
tissue that serves to insulate the body, store energy and provide protection as a cushion
against physical shock (155).
Although the existence of adult stem cells is questioned in the pancreas, studies in
the skin have revealed multiple potential stem cells within both the epidermal and dermal
layers. Within the epidermis, the stem cells are hypothesized to reside in the basal cell
layer, accounting for -10-12% of the cells within this layer (156). Each stem cell is part
of an epidermal proliferating unit and gives rise to keratinocyte transit cells that populate
the column of mature cells from the basal cell layer to the surface of the skin (156-161).
In addition to those found in the epidermis, stem cells are also believed to reside in the
bulge of the hair follicle. During the hair cycle, these cells are activated to proliferate and
differentiate into the many cells of the follicle. In addition, in response to injury, the stem
cells located in the hair follicle bugle have also been shown to function as multipotent
stem cells, giving rise to cells in the epidermis, sebaceous gland and hair follicle (160,
162-166).
For the dermis, the stem cells that repopulate the fibroblast pool are most likely
different from those found in the epidermis and hair follicle. Since fibroblasts remain
fairly quiescent and are stimulated to proliferate only in response to injury (167), stem
cells may only be activated to proliferate during wound healing. One study aimed at
identifying fibroblast stem cells showed that both bone marrow-derived cells and dermal
mesenchymal cells can reconstitute the dermal fibroblast population in response to
wound healing (168). Thus, in addition to differences in the normal proliferation rates of
skin cells, these data suggest that each layer of the skin may have distinct stem cells that
repopulate the tissue. To study the role of homologous recombination within skin cells,
the FYDR mice can be used to measure the frequency of recombinant cells that arise in
adult tissue in vivo. In addition, because recombinant cells are labeled with fluorescence,
the cumulative effects of homologous recombination can be monitored over time,
potentially revealing the role of homologous recombination in skin cells with different
proliferation rates.
Wound Healing
Given the essential role of the skin as a protective barrier against external insults,
it is critical that the skin be able to quickly and effectively repair tissue damage. Wound
healing involves three major overlapping phases: inflammation, proliferation, and tissue
remodeling (167). The inflammatory phase of wound healing is characterized by platelet
aggregation and immune cell infiltration into the wound site. The primary immune cells
at the wound are leukocytes, which are responsible for both fighting pathogens and
stimulating the subsequent stages of wound healing (169). During the proliferation stage
of wound healing, mitogenic cytokines secreted by activated leukocytes induce the
proliferation of many cell types at the site of the wound, including keratinocytes and
fibroblasts (170). In addition to cell proliferation, this stage is also characterized by
wound contraction, reconstitution of the cutaneous barrier and stimulation of
angiogenesis. The final tissue remodeling phase of wound healing involves the
production of collagen into the extracellular matrix and its remodeling, the regression of
the newly formed blood vessels and mature scar formation (167).
Dermal fibroblasts play a critical role in wound healing of the skin. In response to
injury, fibroblasts migrate to the wound site, initiate proliferation, and facilitate wound
contraction. In addition, fibroblasts secrete extracellular matrix components, such as
collagen, that are essential for tissue remodeling and restoration of tissue strength (170,
171). Indeed, the importance of fibroblasts to wound healing is highlighted by the fact
that a reduction in the number and activity of fibroblasts with age is believed to
contribute to the age-associated decrease in tissue repair capacity (167).
In addition to their ability to proliferate in vivo, fibroblasts have also been shown
to proliferate in vitro for -50 population doublings (172). This significant in vitro
proliferative capacity combined with the relative ease with which they are cultured has
enabled fibroblasts to be used extensively for in vitro studies. The ability to induce of
fibroblast proliferation in vivo and in vitro makes them an interesting cell type in which
to study homologous recombination. Using FYDR mice, the role of homologous
recombination can be measured in quiescent fibroblasts within non-injured tissue in vivo.
Subsequently, the ability of fibroblasts to use homologous recombination during cell
division can be measured by stimulating fibroblast proliferation either by culturing them
in vitro or by inducing injury in vivo. Thus, differences in the utilization of homologous
recombination as a double-strand break repair pathways can be probed as cells move
from quiescence to proliferation.
1.6 Mutation Formation in Aging and Cancer
The accumulation of multiple mutations within cells is believed to cause both
aging and cancer (173, 174). During the aging process, mutations accumulate within cells,
causing diminished cell viability or capacity to carry out normal functions (173). Over
time, the number of mutant cells within a tissue can increase, resulting in an overall
reduction of tissue function.
If the mutations that arise with age occur in key tumor suppressor or oncogenes,
they may confer cells with growth and survival advantages. Indeed, malignant
transformation is believed to occur through successive rounds of clonal expansion and
selection of cells with acquired mutations in key tumor suppressor or oncogenes (174-
177). The importance of clonal expansion to tumor formation is highlighted by analyses
of tumors which show that key mutations in tumor suppressors and oncogenes are often
shared by most, if not all, malignant cells within the tumor (178-180). However, although
the clonal expansion of pre-malignant cells is an important precursor to the development
of cancer, no methods have been developed to study clonal expansion within intact
histologically normal tissue.
To study the effect of age on mutant cell frequency in various tissues, a number of
mouse models, including Big Blue (181, 182), Muta Mouse (183), and LacZ (184), have
been used. Intriguingly, the effect of age on mutation frequency appears to be strongly
tissue-dependent, and differences in mutation accumulation do not correlate with
proliferation of cells within the tissue. For example, for tissues with low proliferation
rates, an increase in mutant cell frequency with age is seen in the heart (183, 184) but not
in the brain (181-183, 185). In addition, for tissues that exhibit high proliferation rates,
mutant cell frequency increases in the small intestine (184, 186) but not in the testis (181,
183, 187). Thus, the accumulation of mutations differs among tissues, and factors in
addition to cell proliferation have a large impact on the accumulation of mutant cells with
age.
Most mouse models used for measuring mutations generally require tissue
disaggregation followed by analysis of either cultured primary cells or genomic DNA
(188-191); thus, information about the clonal relationship among mutant cells cannot be
gathered. For example, if the same mutation is observed in multiple cells, it cannot be
determined if the mutation results from multiple independent events (e.g., at a mutation
hot spot) or clonal expansion. Thus, many of the studies analyzing the accumulation of
mutant cells with age either do not differentiate between the contribution of independent
mutation events and clonal expansion (184, 185, 187, 192) or completely remove the
contribution of clonal expansion by specifically analyzing only independent mutation
events (181, 182). However, given the importance of clonal expansion to tumor
formation, analyzing clonal expansion may be important for understanding the
mechanisms of cellular transformation. By using fluorescence as a marker for sequence
changes, the FYDR mice potentially enable the detection of cells harboring recombined
DNA within intact tissue, providing a tool to determine the contribution of clonal
expansion to changes in recombinant cell frequency with age.
1.7 Specific Aims
Homologous recombination has been established as an important modulator of
genomic stability. It is essential for the repair of potentially cytotoxic or mutagenic DNA
damage, such as double-strand breaks and broken replication forks (12). Germline
mutations that result in an impaired ability to repair double-strand breaks by homologous
recombination are either embryonic lethal mice (18-23, 193, 194) or tumor-promoting
(24-28). However, since recombination events are associated with the non-reciprocal
transfer of genetic information from a donor template to the locus of the double-strand
break, every recombination event carries some risk of acquiring deleterious sequence
changes. Indeed, recombination between misaligned sequences can result in insertions,
deletions, translocations, and loss of heterozygosity, sequences changes that can promote
genomic instability (35). Consequently, increased levels of homologous recombination
also lead to an increased risk of cancer (195).
Although homologous recombination may be critical for tumorigenesis, prior to
the development of the FYDR mice (123), studies of recombination in adult tissues in
vivo had not been possible. The FYDR mice carry a direct repeat recombination substrate
in which a homologous recombination event can restore full-length EYFP coding
sequence, resulting in a fluorescent cell (123). Thus recombination events can be detected
in adult tissues in vivo simply by measuring the frequency of fluorescent cells. Through
the work described here, we reveal the effects of cancer risk factors such as age, genetic
predisposition, and exposure on homologous recombination in vivo using the FYDR mice.
Age is an important risk factor for pancreatic cancer (152), with approximately
60% of all cases occurring in patients over 65 years of age (196). In addition, inherited
defects in homologous recombination proteins are known to increase pancreatic cancer
risk (24-26), suggesting that homologous recombination is an important DNA repair
pathway for maintaining genomic stability in pancreatic cells. However, prior to our work
no studies had analyzed recombination in the pancreas. Here, we use FYDR mice to
explore the activity of homologous recombination in the adult pancreas. We develop in
situ imaging methodology for the rapid and sensitive detection of recombinant cells
within intact pancreatic tissue. Using both in situ imaging and tissue disaggregation, we
analyze the effect of exposure to two cancer chemotherapeutic agents, mitomycin-C and
cisplatin, on the frequency of homologous recombination in vivo and demonstrate that in
situ imaging of recombinant cells is more sensitive than tissue disaggregation for
determining environmentally induced recombination events in adult tissues. Furthermore,
we investigate the effects of aging on recombination in the pancreas and determine that a
dramatic increase in recombinant cell frequency occurs with age as the result of both de
novo recombination events and clonal expansion of previously existing recombinant cells.
Since the FYDR mice use fluorescence as a marker for homologous
recombination, expression of the fluorescent protein can affect the apparent frequencies
of recombinant cells. For example, if EYFP is expressed at lower levels, it will be more
difficult to detect recombinant cells. Thus, differences in recombinant cell frequencies
seen with age or with exposure to cancer chemotherapeutics may be due to differences in
the expression levels of the FYDR transgene. To explore the effect of transgene
expression on recombinant cell frequencies, we exploit positive control FYDR-
Recombined mice that carry the full-length EYFP coding sequence in every cell. Because
in positive control mice the EYFP coding sequence is expressed under an identical
promoter and at the same locus as the FYDR recombination substrate in FYDR mice, it is
likely that any differences observed in expression in positive control mice will be
similarly reflected in FYDR mice. In this work, we show inter-mouse and gender-
dependent variation in FYDR transgene expression, examine its impact on data
interpretation, and discuss solutions to overcoming the effects of such variation. In
addition, we analyze EYFP expression in several tissues in addition to the pancreas and
show that some of these tissues may be amenable for studying homologous
recombination using the FYDR mice.
Our studies of aging on recombinant cell frequency in the pancreas revealed the
importance of both de novo recombination events and clonal expansion on the
accumulation of recombinant cells with age. Given the importance of clonal expansion of
mutant cells to cancer formation (174), we set out to develop a method to study clonal
expansion within intact histologically normal tissue. In collaboration with the laboratory
of Peter T. So, an integrated one- and two-photon microscopy imaging system was
created to rapidly identify very rare fluorescent cells within an entire mouse tissue and
subsequently provide 3D images of each fluorescent cell. Using these techniques, we
study the effect of age on clonal expansion of fluorescent cells in the pancreata of FYDR
mice and show that there is a significant increase in the number of cells within
fluorescent cell clusters.
Our analyses of positive control mice show that the pancreas is not the only tissue
amenable for studying homologous recombination in FYDR mice. Thus, we set out to
explore differences in the spontaneous recombinant cell frequency in two tissues,
pancreas and skin. Since it has been shown that tissue-specific differences exist in the
accumulation of mutations with age (186), we also investigate the effect of age on the
accumulation of recombinant cells in pancreas and skin. We found that while
recombinant cells accumulate in the pancreas of FYDR mice, no difference is seen in the
skin with age. To investigate the reasons for the differences in age-dependent
accumulation of recombinant cells in pancreas and skin, we study homologous
recombination in primary fibroblasts from FYDR mice in vitro. We conclude that neither
a decreased rate of homologous recombination, a decrease in spontaneous damage levels
nor a decrease in the ability to cope with exogenous DNA damage contribute to the lack
of accumulation of recombinant skin cells with age in vivo. Rather, we propose that
differences in the accumulation of recombinant cells with age may result from differences
in the ability of recombinant cells to persist and clonally expand within the tissue.
In addition to age and environmental exposures, certain genetic conditions
increase the risk of cancer formation. One gene that appears to be especially critical for
maintaining genomic stability is p53 (197). Indeed, acquired mutations in p53 are seen in
approximately half of all human tumors (198, 199), and inherited mutations in p53 lead to
increased cancer risk (200, 201). A number of studies have analyzed the effect of p53 on
homologous recombination in vitro and in vivo; however, these studies show conflicting
results (103, 107, 202-210). Thus, to determine the effect of p53 on homologous
recombination in vivo, we analyze the frequency of recombinant cells and the number of
recombination foci in pancreata from FYDRY/';p53 / ÷' and FYDRY"';p53 -Y - mice. In
addition, to determine if differences in p53 status may affect homologous recombination
in vitro, we measure the rate of homologous recombination in primary fibroblasts derived
from FYDRY/';p53 +/' and FYDRY/';p53 -Y - mice. These results show that in FYDR mice
p53 status does not significantly affect homologous recombination in pancreatic cells in
vivo or in ear fibroblasts in vitro.
Through the work described here, we aim to understand the role of homologous
recombination in multiple tissues in vivo. By creating techniques to specifically detect
and quantify recombinant cells within intact tissues, we can analyze the impact of
exposure to cancer risk factors on not only de novo recombination events but also clonal
expansion of previously existing recombinant cells. The assays developed here can be
further applied to study homologous recombination in other tissues and by other tumor-
promoting genetic conditions and environmental exposures. Ultimately, these studies
may increase our understanding of the interplay between DNA damage, homologous
recombination, and cancer formation.
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Figure 1-1. Replication fork breakdown leading to the formation of a one-ended double-
strand break. Replication fork encounter with a (A) blocking DNA lesion or (B) single-
strand gap can lead to (C) replication fork breakdown and the formation of a (D) one-
ended double strand end.
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Figure 1-2. Basic mechanisms of double-strand break repair. (A) Homologous
recombination uses homologous sequences present on the sister chromatid or
homologous chromosome as temaplates for double-strand break repair. (B)
nonhomologous end-joining directly rejoins two double-strand ends regardless of
sequence.
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Figure 1-3. Mechanisms of double-strand break repair by homologous recombination.
(A) Synthesis-Dependent Strand Annealing: 1. Resection of the double-strand end to
produce a 3' overhang, 2. Homology searching, strand invasion and strand exchange, 3-4.
DNA synthesis and Holliday Junction formation, 5. Branch migration, 6. Release and
annealing of DNA ends to repair the double-strand break. (B) Double Strand Break
Repair: 1. Resection of the double-strand end to produce a 3' overhang, 2. Homology
searching, strand invasion, strand exchange, and DNA synthesis for one DNA end, 3.
Homology searching, strand invasion, strand exchange, and DNA synthesis for second
DNA end, 4. Cleavage of Holliday Junctions, 5. Formation of crossover or non-crossover
products. (C) Break induced replication: 1. Resection of the double-strand end to produce
a 3' overhang, 2. Homology searching, strand invasion, strand exchange, DNA synthesis
and Holliday Junction formation, 3. Cleavage of the Holliday Junction, 4. Restoration of
the broken replication fork.
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Figure 1-4. Arrangement of the FYDR recombination substrate: large arrows indicate
expression cassettes; yellow boxes show coding sequences; black boxes show positions
of deleted sequences (deletion sizes not to scale). A homologous recombination event
between the two expression cassettes can restore full-length EYFP coding sequence,
resulting in a fluorescent cell. Image depicts recombinant pancreatic cell within freshly
excised tissue.
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Figure 1-5. Histology of a mouse pancreas. The exocrine pancreas contains acinar cells
that secrete hydrolytic enzymes into a series of ducts lined with ductal epithelial cells.
The endocrine pancreas is composed of islets of Langerhans interspersed throughout the
exocrine pancreas. Finally, a system of blood vessels is present within the pancreas to
carry nutrients and signaling molecules to and from the pancreas.
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Figure 1-6. Histology of the mouse skin. The epidermis (E) is the outer most layer of
skin, with a thickness of just a few cell layers. The dermis (D) contains a number ofdifferent cell types including fibroblasts and many cellular structures such as hair follicles(HF).
Chapter II
Age Dependent Accumulation of Recombinant Cells in the
Mouse Pancreas Revealed by in situ Fluorescence Imaging
Chapter 2
2.1 Abstract
Mitotic homologous recombination (HR) is critical for the repair of double-strand breaks,
and conditions that stimulate HR are associated with an increased risk of deleterious sequence
rearrangements that can promote cancer. Because of the difficulty of assessing HR in mammals,
little is known about HR activity in mammalian tissues or about the effects of cancer risk factors
on HR in vivo. To study HR in vivo, we have used Fluorescent Yellow Direct Repeat mice, in
which an HR event at a transgene yields a fluorescent phenotype. Results show that HR is an
active pathway in the pancreas throughout life, that HR is induced in vivo by exposure to a
cancer chemotherapeutic agent, and that recombinant cells accumulate with age in pancreatic
tissue. Furthermore, we developed an in situ imaging approach that reveals an increase in both
the frequency and the sizes of isolated recombinant cell clusters with age, indicating that both de
novo recombination events and clonal expansion contribute to the accumulation of recombinant
cells with age. This work demonstrates that aging and exposure to a cancer chemotherapeutic
agent increase the frequency of recombinant cells in the pancreas, and it also provides a rapid
method for revealing additional factors that modulate HR and clonal expansion in vivo.
2.2 Introduction
Cells are constantly exposed to endogenous and exogenous DNA-damaging agents that
can lead to double-strand breaks, either by causing breaks in both strands of DNA or by causing
replication fork breakdown (1). Homologous recombination (HR) is critical for repairing double-
strand breaks in mammalian cells. By using homologous DNA sequences present on the sister
chromatid or homologous chromosome, damage can be repaired accurately without loss of
sequence information (2, 3). Thus, the frequency of HR reflects both the levels of double-strand
breaks and the ability of cells to use HR during DNA repair.
Although HR is generally error-free, recombination between misaligned sequences can
cause insertions, deletions, and translocations. Furthermore, recombination between homologous
chromosomes can lead to loss of heterozygosity (4), and HR has been estimated to be the
underlying cause of loss of heterozygosity 25-80% of the time in mammalian cells (e.g., see (5)).
Germ-line mutations in genes that modulate the frequency of HR are associated with an
increased risk of cancer. For example, inherited mutations in the HR helicases BLM and WRN
lead to increased rates of HR (6, 7) and increase the risk of cancer (8).
Whereas too much HR can be problematic, too little HR can also destabilize the genome,
possibly as a result of nonhomologous end-joining of DNA ends created at broken replication
forks (4, 9). In the pancreas, inherited mutations in BRCA1 (8), BRCA2 (10), and FANCC (11)
increase the risk of pancreatic cancer, and loss of function of these genes suppresses HR (12-14),
causing an increased frequency of tumorigenic sequence rearrangements (15, 16). Although
these findings suggest that HR is critical for maintaining genomic integrity in the pancreas, it had
not been shown that HR is an active pathway in mature pancreatic cells and no studies had
explored the effects of cancer risk factors on potentially mutagenic HR events in the pancreas.
With a 5 year survival rate of less than 5%, pancreatic cancer remains one of the deadliest
cancers in the United States (17, 18). One important risk factor for pancreatic cancer is aging
(19). To our knowledge, mutation frequency has not been reported in the pancreas (20), so the
effect of age on pancreatic mutation frequency was not known. However, a number of studies
have investigated the impact of age on mutation frequency in other cell types. For example, the
frequency of loss of heterozygosity increases by -~10-fold with increasing age in lymphocytes
(21, 22). Furthermore, a significant fraction of these loss of heterozygosity events are because of
mitotic recombination, suggesting that HR contributes to gene inactivation during aging (21-23).
In this study, we have explored the effects of aging and exposure to a cancer
chemotherapeutic agent on the frequency of HR in the mouse pancreas by exploiting mice in
which HR at an integrated transgene yields a fluorescent phenotype (24). Furthermore, we
describe novel methodology for rapid and sensitive detection of recombinant cells within intact
pancreata.
2.3 Materials and Methods
Animals
C57BL/6 FYDR mice have been described in ref. (24). Positive control FYDR-
recombined (FYDR-Rec) mice arose spontaneously from an HR event in a FYDR parental
gamete, and all cells within these mice carry the full-length EYFP coding sequence. FYDR
cohorts had an -1:1 ratio of males to females (preliminary data suggests that there may be a
difference in EYFP expression levels among males and females). Controls were sex- and age-
matched, except the aged negative control C57BL/6, which were 47-85 weeks old, and the aged
positive control FYDR-Recombined mice, which were 52 weeks old.
Flow Cytometry
Pancreata were isolated and placed in ice-cold PBS containing 0.01% soybean trypsin
inhibitor (Sigma). Almost all samples were analyzed by flow cytometry after imaging. Pancreata
were minced and divided into two samples. Samples were shaken (150 cycles per minute) in 5 ml
of 2 mg/ml collagenase V (Sigma) in Hanks' buffered salt solution (Invitrogen) at 370C for 20
min. Triturated tissue was filtered (70 pm), and 10 ml of DMEM-F 12 (Sigma) supplemented
with 20% FBS (Atlanta Biologicals, Lawrenceville, GA) was added. Cells were pelleted,
resuspended in 400 pl of OptiMEM (Invitrogen), filtered (35 pm), and analyzed by flow
cytometry as described in ref. (24). On average, -~1 million cells were analyzed per sample.
Fluorescence Intensity Measurements
Geometric mean of fluorescence intensity of pancreatic cells in the R2 region of juvenile
and aged mice was calculated by CellQuest acquisition and analysis software on the Becton
Dickinson FACScan flow cytometer.
Imaging
Pancreata were isolated as described. Nuclei were stained with 50 pg/ml Hoechst 33342
(Sigma). Whole pancreata pressed between glass slides separated by 0.5 mm spacers were
imaged on a Nikon E600 microscope with a SPOT RT camera (Diagnostic Instruments, Sterling
Heights, MI) with a Nikon xl objective. Images were manually compiled to cover the entire
visible surface area. SPOT Advanced (Diagnostic Instruments) was used to colorize black and
white images. Filters included: visible light; UV (excitation, 330-380 nm; emission, 420 nm);
red (excitation, 540/25 nm; emission, 605/55 nm); and EYFP (excitation, 460-500 nm; emission,
510-560 nm). Images were collected by using a fixed aperture time. For foci counting, Adobe
Photoshop 5.0 (Adobe Systems, San Jose, CA) was used to optimize brightness and contrast. For
images collected with the EYFP filter, identical adjustments were made for all images. Similarly,
for images collected with the red filter, brightness was optimized and identical adjustments were
made for all red fluorescence images. For pancreata with foci in the red channel, images taken
under the red filter were inverted to create negatives that were merged with images taken under
the EYFP filter. Foci were counted manually. Similar results were obtained in a subset of blinded
samples. The area of compiled pancreata images was determined by using Scion Image Beta 4.02
Win (Scion, Frederick, MD) by manually tracing the pancreas edge
Mitomycin-C treatment
Five- to 6-week-old FYDR mice were i.p. injected with 2 mg/kg of body weight of 0.5
mg/ml MMC (Sigma) in PBS. Mock-treated controls were injected with equal volumes of PBS.
Mice were analyzed 3.5 weeks after injection.
Histology
Frozen sections (5 jpm) were imaged at x40 with an EYFP filter (excitation, 460-500 nm;
emission, 515 nm) on aNikon E600 microscope. SPOT Advanced (Diagnostic Instruments) was
used to colorize images. Sections were subsequently stained with H&E, imaged, and manually
overlaid. Histology was assessed by Arlin Rogers (Massachusetts Institute of Technology)..
Statistics
Recombinant cell frequency follows a non-normal distribution (Fig. 2-1C). Therefore,
frequencies among cohorts were compared using a one-tailed Mann-Whitney test (for both flow
cytometry and foci data). When comparing the frequency of fluorescent cells among positive
control cohorts, a two tailed Student's t test was performed.
2.4 Results
Flow Cytometry Analysis of Homologous Recombination Events in Adult Pancreatic Cells
The fluorescent yellow direct repeat (FYDR) mice carry a direct repeat recombination
substrate in which an HR event can restore full-length enhanced yellow fluorescent protein
(EYFP) coding sequence (24) (Fig. 2-1A). Because HR had not been studied in primary
pancreatic cells, we first set out to determine whether HR is an active process in the pancreas. To
establish flow cytometry parameters, we compared fluorescence intensities in disaggregated
whole pancreata from negative control and positive control mice (Fig. 2-1B). To quantify
fluorescent recombinant cells, a region (R2) was created that excludes negative control cells (Fig.
2-1B). We analyzed >34 million cells from 33 negative control pancreata by flow cytometry, and
only one cell appeared in the R2 region, indicating an extremely low background. Analysis of
100 mice aged 4-10 weeks shows the median frequency of recombinant pancreatic cells is five
per million (Fig. 2-1C). In addition, the recombinant cell frequency is highly variable among
mice (Fig. 2-1C), which is consistent with the possibility that recombinant cells that arise at
different times during growth can clonally expand.
In Situ Detection of Recombinant Pancreatic Cells
To learn more about the timing of HR events, and to reveal the cell types in which they
occur, methodology was developed for direct detection of recombinant cells in situ. Under an
epifluorescent microscope, negative control pancreata are essentially nonfluorescent when
viewed with an EYFP filter, whereas Hoechst 33342-stained nuclei fluoresce under UV (Fig. 2-
2A). In contrast, in positive control pancreata, much of the tissue is brightly fluorescent (Fig. 2-
2B). In FYDR pancreata, yellow fluorescent foci are readily apparent (Fig. 2-2C). At a higher
magnification, it becomes clear that these fluorescent foci are actually single isolated cells and
small clusters of cells (Fig. 2-2D), indicating that recombinant cells can be directly detected
within intact tissue via microscopic examination of intact pancreata.
To explore which cell types recombine, frozen sections of pancreata were analyzed. By
overlaying fluorescence and H&E-stained images, histological analysis of pancreata from
positive control mice revealed that acinar, islet, and ductal cells can fluoresce (data not shown).
In pancreata of FYDR mice, EYFP fluorescence is confined within cell boundaries and
recombinant cells are acinar cells (no islet or ductal cells were detected among 43 independent
foci) (Fig. 2-2E). Therefore, the fluorescent foci seen within the pancreas of FYDR mice are
most often due to fluorescent acinar cells.
To standardize conditions for foci quantification, pancreata were uniformly compressed
to a thickness of 0.5 mm, and composite images that cover one side of the pancreatic surface area
were created (Fig. 2-3A). Comparison of both sides of the same pancreas showed that similar
frequencies of recombinant cells were detected on both sides (data not shown; note that most foci
detected on one side could not be detected on the other side because of sample thickness). In
negative control mice, background fluorescence was occasionally observed and generally emitted
under multiple filters. To reduce background fluorescence, images collected under a red filter
were inverted, and these negatives were then merged with images taken with an EYFP filter (Fig.
2-3B). Using this subtraction methodology, we analyzed 24 negative control animals, and no foci
were detected. These methods make it possible to specifically detect EYFP fluorescence and thus
provide a means for rapid quantification of recombinant cells in situ.
DNA-damage Induced Recombination in Pancreatic Cells
To determine whether HR can be induced in postnatal pancreatic cells, 5- to 6-week-old
FYDR mice were injected with the recombinogenic interstrand cross-linking agent mitomycin-C
(MMC). The median frequencies of recombinant cells by flow cytometry (Fig. 2-4A) and of
recombinant foci by in situ imaging (Fig. 2-4B) were higher among the MMC-treated mice (note
the logarithmic scale). It is formally possible that the increased frequency of recombinant cells
after MMC treatment is because of increased EYFP expression. To explore this possibility, we
exploited positive control animals in which all cells carry the recombined substrate (full-length
EYFP). Flow cytometry of pancreatic cells from mock- and MMC-treated positive control mice
revealed that there was no statistically significant difference in EYFP expression between the
cohorts (data not shown). Thus, we conclude that the increase in recombinant cell frequency after
MMC treatment is the result of an induction of recombinant cells, indicating that the FYDR
model specifically detects HR events, and that HR is an active repair process in the postnatal
pancreas
Interestingly, MMC induction is statistically significant only when analyzed by in situ
imaging. It is noteworthy that mice with a similar number of recombinant foci can show a broad
range of recombinant cell frequencies when analyzed by flow cytometry, possibly because a
single focus may contain many recombinant cells. Thus, when studying the effects of an
environmental exposure by flow cytometry, it should be noted that large foci can potentially
mask the induction of multiple smaller foci. Although both flow cytometry and in situ imaging
detect recombinant cells, in situ imaging may be a more sensitive method for detecting exposure-
induced recombinant cells (e.g., independent HR events).
Effect of Aging on Recombinant Cell Frequency
Age is an important risk factor for cancer. To explore the effects of aging, recombinant
foci were quantified in three different age groups: juvenile (4 weeks old), adult (9 weeks old),
and aged (67-74 weeks old). Whereas the number of foci detected by in situ imaging varied
among individual animals within each age group, the median clearly increased with age (Fig. 2-
5B). This increase was especially evident when examining images ofpancreata with the highest
frequency of recombinant foci from each age group (Fig. 2-5A). Relative to juvenile mice, the
median number of recombinant foci increased -4- and -16-fold in adult and aged mice,
respectively (Fig. 2-5B), demonstrating that recombinant cells accumulate with age.
During aging, the mouse pancreas continues to grow (Fig. 2-5C) (25, 26), which raises
the possibility that the increase in the number of foci is because of the increase in surface area of
pancreata (Fig. 2-5C). After correcting for the total surface area, the median frequencies of
recombinant foci per cm 2 in adult and aged cohorts are still significantly higher than juvenile
mice (~2 and ~9 fold higher, respectively; Fig. 2-5D), suggesting that new recombination events
contribute to the accumulation of recombinant cells with age.
As an alternative approach for analyzing the effects of aging on HR, disaggregated
pancreatic cells were quantified by flow cytometry (Fig. 2-5E). Similar trends in the frequency of
recombinant cells were observed with age. Relative to juvenile mice, the median frequency of
fluorescent cells per million increased in adult and aged mice by ~8- and -26-fold, respectively.
A comparison of the mice with the highest frequencies from the young vs. the aged cohorts
shows there are 14 vs. 914 recombinant cells per million, respectively (note the logarithmic
scale). Together, these data indicate that as mice age, the frequency of cells harboring DNA
sequence rearrangements increases significantly.
To determine whether the increased frequency of recombinant cells with age is because of
an increase in EYFP expression, we analyzed pancreata from positive control mice. Although
EYFP expression varies greatly among individual positive control mice (which undoubtedly
contributes to variation in the frequency of fluorescent cells among the FYDR mice), there were
no statistically significant differences in expression levels among the young, adult, and aged
cohorts (data not shown). Because expression of the FYDR locus does not increase with age, we
conclude that the increase in recombinant cell frequency with age is the result of the
accumulation of recombinant cells in the pancreas.
Clonal Expansion of Recombinant Cells
Clonal expansion of mutant cells is an important precursor to the development of cancer
(27). To explore the possibility that recombinant cells clonally expand with age, images from all
juvenile and aged animals were carefully examined to identify the five largest foci from within
each cohort. Comparison of the foci images revealed that foci are clearly much larger in aged
animals (Fig. 2-5F). Given that the geometric mean fluorescence intensity of recombinant cells is
not significantly different among cohorts (data not shown), the observed increase in foci sizes
cannot be due to increased brightness. It is formally possible that the increase in recombinant foci
sizes is the result of multiple independent recombination events occurring in neighboring cells.
However, because the frequency of recombinant cells in the pancreas is -5 per million, the
probability that two adjacent recombinant cells occurred from independent events is -~1 in 1010
(assuming that each cell touches -10 neighbors), making it virtually impossible that multiple
adjacent recombinant cells in large foci occurred independently. These data indicate that
recombinant cells can clonally expand during aging, which suggests that there is clonal
expansion throughout the pancreas that can be visualized in cases where the progenitor cell is
fluorescent.
2.5 Discussion
With a 5 year survival rate of less than 5% (17, 18), pancreatic cancer remains a fatal
disease. Pancreatic cancer is caused by the accumulation of genetic mutations in a single cell
lineage (e.g., activation of K-ras and inactivation of pl6, p53, Smad4, and BRCA2) (28). The
probability that multiple mutations occur in the same lineage depends upon both the mutation
rate and the total number of cells that harbor tumorigenic mutations (27, 29). Therefore,
increasing either the mutation rate or the number of mutant cells (by clonal expansion)
concomitantly increases the risk of acquiring subsequent, and possibly transforming, mutations in
the same cell lineage.
Among >2000 rodent experimental records in which mutation frequencies have been
assessed using transgenic animals, none describe the mutation frequency in the pancreas (20).
Here, we have used FYDR mice to study one important class of mutations, HR events. When
both in situ imaging and flow cytometry are used, results show that the number of recombinant
cells increases with age, and a comparison of the sizes of recombinant foci in juvenile and aged
mice shows that pancreata of aged mice have larger foci. Therefore, as mice age, both de novo
HR events and clonal expansion contribute to the overall increase in the number of pancreatic
cells harboring rearranged DNA.
Within all cohorts, a wide range of recombinant cell frequencies is observed. This
intermouse variation may result from differences in recombination rates, fluctuations in foci sizes
caused by clonal expansion, or variation in expression of EYFP. Although we have not yet tested
for differences in recombination rates among individual mice, it is clear that clonal expansion can
contribute to variation in the total number of recombinant cells. In addition, the positive control
mice indicate that variable levels of EYFP expression also contribute to intermouse variation.
Although we do not yet know the cause for the variegated expression in the positive control mice,
recombination can still be studied by ascertaining whether a variable of interest affects
expression in a cohort of positive control animals. For example, in these studies, EYFP
fluorescence does not increase with age, indicating that the increased frequency is due to HR.
Indeed, expression may even decrease with age, so the effect of age on the accumulation of
recombinant cells may actually be underestimated.
Histological analysis of-40 foci revealed that all recombinant fluorescent cells are acinar
cells. Although the majority (80-90%) of human pancreatic neoplasms are ductal pancreatic
adenocarcinomas (18), there is debate over the actual origin of cells that lead to ductal
adenocarcinomas. Interestingly, acinar cells can transdifferentiate into ductal cells both in vitro
and in vivo (30-32). Furthermore, expression of activated K-ras in pancreatic acinar cells has
been shown to induce preinvasive pancreatic neoplastic lesions (31). Therefore, genetic changes
in acinar cells may contribute to tumor formation. Regardless of whether acinar cells are the
precursors of ductal adenocarcinomas, genetic and environmental conditions that induce HR in
acinar cells may do so in other pancreatic cell types as well. Therefore, detection of HR in acinar
cells may be a gauge of genetic insult to the pancreas as a whole, making the FYDR mice
potentially useful as sensors of pancreatic genotoxins.
Other mouse models, including Big Blue@ (33, 34), MutaTMMouse (35), and LacZ (36),
have been used to examine changes in the frequency of point mutations and small deletions with
age. The effect of age on these classes of mutations appears to be strongly tissue-dependent. In
certain tissues, such as brain and testis, the mutant frequency remains fairly constant (33-35). In
contrast, for liver and bladder, mutant cell frequency increases with age similar to what has been
observed for the pancreas in these studies (33-35). It is interesting to speculate that for tissues in
which spontaneous mutations accumulate with age, mutagenic exposures during adult life may
have a greater influence on cancer risk. Indeed, smoking is an important risk factor for liver,
bladder, and pancreatic cancer, and has less of an effect on the risk of brain or testicular cancer
(37).
HR events are an important class of mutations that are known to promote cancer (4, 38).
Here we have shown that detection of recombinant cells in FYDR mice by in situ imaging and
flow cytometry can be used to monitor the effects of cancer risk factors on HR. Compared with
analysis by flow cytometry, in situ detection improves the sensitivity for detecting new mutation
formation (e.g., small foci) that can be masked by previously existing larger foci upon tissue
disaggregation. Furthermore, because the accumulation of recombinant cells can be monitored
over months and even years, long-term effects of both acute and chronic exposures relevant to
cancer can also be studied. Although small differences in recombination rate may not be
immediately reflected as differences in mutant cell frequency, these changes in recombination
rate may result in large changes in mutant cell frequency over time. In summary, we have
explored how a key risk factor for pancreatic cancer, aging, affects the frequency of cells
harboring recombined DNA. The results of these studies demonstrate that HR is an active
process in the adult pancreas, and that cells harboring sequence rearrangements can persist and
clonally expand. Furthermore, the methodology used in these studies can now be applied to
explore how additional genetic and environmental risk factors modulate double-strand break
formation and repair by HR.
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Figure 2-1. FYDR system and analysis of pancreatic cells by flow cytometry. (A)
Arrangement of the FYDR recombination substrate. Large arrows indicate expression
cassettes; yellow boxes show coding sequences; black boxes show positions of deleted
sequences (deletion sizes not to scale). For a more complete description of HR
mechanisms that can restore full-length EYFP coding sequences, see Jonnalagadda et al.(39). (B) Flow cytometry results of disaggregated pancreatic cells. Axes indicate relative
fluorescence intensity at 515-545 nm (FL1) vs. 562-588 nm (FL2). R2 region delineates
EYFP-positive cells. Representative data are shown for a negative control mouse, a
positive control FYDR-recombined mouse, and an FYDR mouse. For clarity, data for
individual cells (dots) have been darkened in the FYDR R2 region. Percentages of
fluorescent cells identified in the R2 region are indicated for the positive and negative
controls. Cell images are representative of disaggregated pancreatic cells from an FYDR
mouse taken at x40 with phase contrast or an EYFP filter (515 nm). Image of a
fluorescent cell under an EYFP filter is colorized. (C) Spontaneous frequency of
recombinant pancreatic cells per 106 as determined by flow cytometry for 100 4- to 10-
week-old FYDR mice. n = number of independent samples.
FFigure 2-2. Analysis of fluorescent foci in mouse pancreata. For analysis of freshly
excised tissue, images show overlays of EYFP- (510-560 nm) and UV- (420 nm) filtered
images. Nuclei are stained with Hoechst 33342. (A-C) Portions of negative control (A),
positive control (B), and FYDR (C) mouse pancreata imaged at xl. (Scale bar, 1 mm.)
Brightness and contrast for UV-filtered images were adjusted equivalently. For EYFP
images, brightness and contrast for negative control and FYDR (5-s exposure) images
were adjusted equivalently. To avoid overexposure of the positive control, a shorter
exposure time was used (1 s) and brightness and contrast were not adjusted. (D) Images
of fluorescent recombinant cells in freshly excised tissue at x40. (Scale bar, 10 jpm.)
Brightness and contrast were optimized for each image. (E) Histological images were
collected at x40. (Scale bar, 30 pm.) (Upper) H&E-stained section. (Lower) Overlay of
H&E and fluorescence imaged under an EYFP filter (515 nm). Brightness and contrast of
fluorescence were optimized. EYFP fluorescence is colorized.
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Figure 2-3. Imaging methodology for quantifying recombinant cells in whole pancreata.(A) Compiled image of 9-week-old FYDR pancreas at xl taken under visible light (Left)
and an EYFP filter (510-560 nm) (Right). (Scale bar, 1 cm.) The edge of the pancreatic
tissue is outlined. (B) Method for reducing background fluorescence. (Upper)
Background fluorescence appears brightly under EYFP (510-560 nm, column 1) and red(605/55 nm, column 2) filters. The red-filtered image is inverted (column 3) and merged
with the EYFP-filtered image (column 4). (Lower) Similar analysis of an EYFP focus.
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Figure 2-4. MMC-induced HR in mouse pancreata. Medians are indicated by black bars.
Points on the x axis indicate individual mice with zero recombinant cells. (A) Frequency
of recombinant cells per million as determined by flow cytometry for mock-treated (n
35) and MMC-treated (n = 34) FYDR mice (P = 0.06). (B) Recombinant foci per
pancreas detected by in situ image analysis for mock-treated (n = 24) and MMC-treated
(n = 23) FYDR mice. * MMC-treated cohort is statistically significantly higher than
mock-treated cohort (P < 0.05).
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Figure 2-5. Effects of aging on the frequency of recombinant cells in the pancreas. (A)
Compiled images for juvenile (4 weeks old) (Left), adult (9 weeks old) (Center), and aged(64-72 weeks old) (Right) FYDR mice. Examples of pancreata with the highest number
of recombinant foci for each cohort are shown. Images were collected at xl with an
EYFP filter (510-560 nm). (Scale bar, 1 cm.) The edge of the pancreatic tissue is outlined.(B) Recombinant foci per pancreas detected by in situ image analysis for juvenile (n =25), adult (n = 24), and aged (n = 16) mice. (C) Weight (mg) and area (cm 2) of mouse
pancreata for juvenile (n = 25), adult (n = 25), and aged (n = 17) cohorts. (D)
Recombinant foci per squared centimeter for juvenile (n = 25), adult (n = 24), and aged(n = 16) mice. (E) Frequency of recombinant cells per million as determined by flow
cytometry for juvenile (n = 24), adult (n = 24), and aged (n = 16) mice. (B-E) * Adult
cohort is significantly higher statistically than juvenile cohort (P < 0.05). ** Aged cohort
is significantly higher statistically than juvenile and adult (P < 0.05) cohorts. Medians are
indicated by black bars. Points on the x axis indicate individual mice with zero
recombinant cells detected. (F) Images of the five largest foci among all juvenile (Left)
and all aged (Right) mice taken under an EYFP filter (510-560 nm) at xl. (Scale bar, 100
pm.) Brightness and contrast were not adjusted.
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Chapter III
Applications of Fluorescence for Detecting
Rare Sequence Rearrangements in vivo
Chapter 3
3.1 Abstract
Homologous recombination (HR) is an important pathway for the accurate repair of
potentially cytotoxic or mutagenic double strand breaks (DSBs), as well as double strand
ends that arise due to replication fork breakdown. Thus, measuring HR events can provide
information on conditions that induce DSB formation and replicative stress. To study HR
events in vivo, we previously developed Fluorescent Yellow Direct Repeat (FYDR) mice in
which a recombination event at an integrated transgene yields a fluorescent signal. Recently,
we published an application of these mice demonstrating that fluorescent recombinant cells
can be directly detected within intact pancreatic tissue. Here, we show that in situ imaging is
a more sensitive method for detecting exposure-induced recombinant cells, yielding
statistical significance with smaller cohorts. In addition, we show inter-mouse and gender-
dependent variation in transgene expression, examine its impact on data interpretation, and
discuss solutions to overcoming the effects of such variation. Finally, we also present data on
enhanced yellow fluorescent protein (EYFP) expression, showing that several tissues, in
addition to the pancreas, may be amenable for in situ detection of recombinant cells in the
FYDR mice. The FYDR mice provide a unique tool for identifying genetic conditions and
environmental exposures that induce genotoxic stress in a variety of tissues.
3.2 Introduction
Mitotic homologous recombination (HR) is critical for the repair of genome
destabilizing DNA damage, including double strand breaks (DSBs) and interstrand cross-
links. These DNA lesions can be caused by environmental exposures, such as radiation or
chemotherapy, and by endogenous cellular metabolites, such as reactive oxygen species (1-4).
In addition, DSBs can occur as the result of DNA processing. For example, replication fork
encounter with a DNA lesion or a single strand gap can cause replication fork breakdown,
creating a double strand end (5-9). HR is the only DNA repair pathway that can accurately
repair replication fork associated double strand ends (1, 2). With its critical role in the repair
of replication-dependent and -independent DSBs, it is not surprising that mitotic HR is
critical to human health (10-14).
In addition to HR, cells use another DNA repair pathway, nonhomologous end-
joining (NHEJ), to recognize and repair DSBs. In contrast to HR which uses homologous
sequences as templates for repair, NHEJ directly rejoins DSBs, regardless of sequence (15,
16). In order to maintain genomic stability, cells maintain an appropriate balance between
NHEJ and HR in the repair of DSBs. NHEJ is the preferred pathway during Go/G 1 phases of
the cell cycle, whereas HR is critical during late S/G2 (17). Specifically, HR repairs broken
replication forks that arise during S phase by reinserting broken ends into their respective
sister chromatids. If the double strand ends were instead acted upon by NHEJ, the mis-
joining of broken ends from independent replication forks at two different loci will inevitably
lead to large scale sequence rearrangements that may be tumorigenic or cytotoxic. On the
other hand, since a significant portion of the human genome is composed of repetitive
elements, the repair of DSBs during Go/G 1 phases by HR could lead to exchanges between
misaligned sequences that promote tumorigenic aberrations (18). Thus, many inherited
mutations in genes that modulate HR, whether up or down, are associated with an increased
risk of cancer, (13, 14, 19) and defects in HR proteins are also often seen in sporadic cancers
(20-23).
Ironically, although DNA damage that inhibits replication can induce tumor-
promoting sequence rearrangements, many agents used to treat cancer are in fact DNA
damaging-agents that inhibit replication fork progression. Thus many chemotherapeutic
agents are highly recombinogenic (24-29). Interestingly, elevated levels of HR proteins
within tumor cells are associated with an increased resistance to many cancer
chemotherapeutics (30-35) and a poor prognosis for cancer survival (36). In contrast, cancer
cells deficient in HR (e.g., breast tumors with BRCA2 mutations (37, 38)) are rendered
sensitive to chemotherapeutic agents that induce replication fork breakdown (39-42).
Therefore, knowledge about HR capacity is relevant both to one's risk of developing cancer
(13, 14, 19) and to the response of a tumor to chemotherapy (39-43).
Although HR is an important pathway for overcoming the potential lethality and
mutagenicity of replicative stress, studying HR has been difficult since many key HR
proteins are either essential for viability (44-49) or possibly sufficiently redundant that their
absence does not fully reveal the role of this pathway in vivo. An alternative approach for
studying HR is to measure DNA sequence rearrangements that result from HR events.
Toward this end, we have developed Fluorescent Yellow Direct Repeat (FYDR) mice that
enable the detection of HR events in vivo.(50) FYDR mice carry a direct repeat
recombination substrate that contains two differently mutated copies of the coding sequence
for enhanced yellow fluorescent protein (EYFP). An HR event can restore full length EYFP
coding sequence, thus yielding a fluorescent cell (Fig. 3-1A). One exciting advantage of
using fluorescence as a marker for sequence changes is that cells harboring recombined DNA
can potentially be detected within intact tissues.
3.3 Results
Advantages of In Situ Detection
Recently, we have shown that fluorescent recombinant cells are directly detectable
within pancreatic tissue (51). Examination of aged mice by in situ imaging revealed a
dramatic increase in not only the number but also the size of recombinant cell clusters (Fig.
3-1B), indicating that both de novo events as well as clonal expansion contribute to the
overall increase in the frequency of recombinant cells with age. The advantage of being able
to detect the accumulation of de novo recombination events is that it enables the study of the
cumulative effects of long term exposures on recombination. In addition, the ability to detect
clonal expansion enables the identification of clonal cell populations in normal tissues (52).
Both the formation of new genetic changes and clonal expansion of cells with preexisting
genetic changes contribute to cancer development. Therefore, being able to study conditions
that induce new genetic changes as well as stimulate clonal outgrowth will likely yield
interesting insights into the earliest steps of cancer formation.
Although the FYDR mice have been used to study the accumulation of
environmentally induced recombinant cells in adult mice (51), one limitation to the
sensitivity of this assay is the variation in the frequency of spontaneous recombinant cells
among mice. When the tissue is disaggregated and subsequently analyzed by flow cytometry,
large recombinant cell clusters can lead to a high frequency of fluorescent recombinant cells,
which could mask the induction of de novo exposure-induced recombinant cells. Therefore,
the detection of discrete recombinant cell clusters by in situ imaging may be a more sensitive
method for detecting de novo recombination events. We tested this hypothesis by comparing
our ability to detect HR events after treatment with the DNA cross-linking agent
mitomycin-C (MMC). Analysis by both in situ imaging and flow cytometry show an
induction in recombinant cells in vivo. However, with ~24 mice per cohort, the induction was
statistically significant only when foci were analyzed in situ (Fig. 3-2A). Statistical
significance by flow cytometry was observed when approximately twice as many (-47) mice
per cohort were analyzed (Fig. 3-2B). These data show that because independent mutation
events can be distinguished, in situ imaging provides a more sensitive method for
determining environmentally induced mutations in adult tissues. Interestingly, many
previously published mutation studies have been done by analyzing DNA from disaggregated
tissue (e.g., Aprt, Tk, Big Blue, Muta Mouse, GptA) (53-55), an approach that limits
information about the clonal relationship among mutant cells. The observation that in situ
analysis is more sensitive than tissue disaggregation for detecting environmentally induced
mutations raises the possibility that previous studies of disaggregated tissues may
underestimate the impact of some environmental exposures. It is noteworthy that the
techniques described here are not limited to HR and could potentially be applied to studies of
other types of mutations.
Controlling For Variation in Transgene Expression Levels
In the course of studying MMC-induced recombination, we noticed an apparent
difference in foci frequencies amongst males and females. Indeed, closer examination of
recombinant foci in pancreata of FYDR mice reveals a statistically significant difference in
the number of recombinant foci between males and females (Fig. 3-3A), even without
exposure to exogenous DNA damaging agents. Although this difference in recombinant foci
may be the result of differences in HR, it is also possible that this difference results from
differences in the ability to detect fluorescent cells (e.g., differences in expression levels of
EYFP). To explore the possibility that the higher number of recombinant foci in female
pancreata may be due to higher levels of FYDR transgene expression, we exploited positive
control FYDR-Recombined (FYDR-Rec) mice. FYDR-Rec mice arose spontaneously from
an HR event in a FYDR parental gamete. Thus, all cells in FYDR-Rec mice carry the full-
length EYFP coding sequence under the identical promoter and locus as the FYDR mice and
have the potential to express EYFP. Therefore, the FYDR-Rec mice are the perfect positive
control for FYDR transgene expression, and expression of the FYDR transgene can be
analyzed simply by looking at expression of EYFP. We have measured the percentage of
fluorescent cells from over 50 disaggregated positive control FYDR-Rec pancreata (Fig. 3-
3B). It is noteworthy that regardless of sex, pancreatic cells show a range of EYFP
expression levels. However, the average percentage of cells expressing EYFP was
statistically significantly higher in female mice. Therefore, the male-female difference in
recombinant foci is at least partially due to differences in expression.
In addition to gender, exposures may also affect expression of the FYDR transgene.
Thus, in addition to its effect on recombination, the effect of any condition on transgene
expression should be determined concurrently in a cohort of FYDR-Rec mice. For example,
to determine the effect of MMC treatment on FYDR transgene expression, we included
mock- and MMC-treated FYDR-Rec cohorts in our study. Analysis of disaggregated FYDR-
Rec pancreata showed that MMC treatment did not lead to any statistically significant change
in the percentage of fluorescent cells (Fig. 3-3C). These studies indicate that the increase in
recombinant cells after MMC treatment in FYDR mice is indeed due to HR and not to an
increase in expression of the FYDR transgene.
In the FYDR mice, expression of EYFP is controlled by the cytomegalovirus
enhancer/chicken beta actin (CAG) promoter. Although this promoter has previously been
shown to be ubiquitously expressed in all cell and tissue types (56), this is not the case in our
particular model. Histological analysis shows significant variation in expression levels even
among the same cell type within a tissue. The variability in expression may be the result of
the locus of integration and the number of integrated transgene copies (note that in these
mice, a single copy of EYFP is expressed (50)). Such expression variability is unlikely to be
unique to this particular mouse model. Transgene expression variability within a single tissue
type can have a tremendous impact on experimental design and data interpretation, resulting
in the need to explore and control for inter-mouse variation in transgene expression. In our
system, when comparing HR among different genetic conditions or environmental exposures,
inter-mouse variation in transgene expression can be overcome by using appropriate FYDR
cohort sizes and by using the positive control FYDR-Rec mice to determine the effect of a
condition on transgene expression. Thus, the FYDR and FYDR-Rec mice together provide a
unique system for determining the effect of any genetic condition or environmental exposure
on HR.
Future Applications: Studies of Homologous Recombination in Multiple Tissues
In our studies, we have focused on analyzing recombination in the pancreas,
cutaneous tissue, and cultured primary ear fibroblasts (50, 51, 57). In addition to the pancreas
and skin, recombination in other tissues of the FYDR mouse can potentially be studied.
However, one limitation of using fluorescence as a measure of recombination is that EYFP is
not expressed equally in all cell types. In order to detect rare recombinant cells (-1-5/106),
both a high signal to noise ratio and a large number of analyzable cells is required. To learn
more about which tissue types are amenable for analysis, we examined the fluorescence
signal to noise ratio in a variety of tissues from FYDR-Rec and negative control C57B1/6
mice. These studies revealed that EYFP is detectable in multiple tissue types, but that the
percentage of cells expressing EYFP and the brightness of EYFP expression are highly
variable within each tissue (Fig. 3-4) and among individual mice (data not shown). In the
pancreas (Fig. 3-4A), EYFP expressing cells are generally extremely bright. Similar to the
pancreas, expression of EYFP in skeletal muscle is uniform and comparable in brightness
(data not shown). In contrast, EYFP expression is seen sporadically in renal tubular epithelial
cells (Fig. 3-4B), in biliary epithelial cells and in hepatocytes within the liver (data not
shown), and in alveoli and bronchiolar epithelial cells within the lung (Fig. 3-4C). Within
these tissues, however, expression is generally dimmer than in the pancreas. Within the brain,
EYFP expression is dim and limited to cells consistent with Purkinje cells (data not shown),
although more experiments are needed to determine cell type. Lastly, in addition to tissue
sections, flow cytometry analysis of cells from blood and bone marrow show that certain cell
types within these tissues also express EYFP (data not shown). Since the ability to study
recombination in certain tissues of FYDR mice depends upon the brightness of fluorescence,
the fraction of cells expressing the FYDR transgene, and the total number of cells that can be
analyzed from a given tissue, it may be more difficult to detect rare recombinant cells in
tissues where EYFP expression is either dim or sporadic. However, given the sensitivity of
epifluorescence for being able to detect as few as one recombinant cell within an entire
pancreas (-3x107 cells (58)) these preliminary studies suggest that with appropriate imaging
techniques it may be possible to use the FYDR mice to study HR in a variety of tissues.
3.4 Discussion
Using fluorescent proteins to mark cells that have undergone an HR event makes it
possible to detect rare recombinant cells that arise in vivo and to learn about the underlying
cell types that have undergone a recombination event. Furthermore, in situ detection enables
differentiation between de novo and clonally expanded recombinant cells. By combining both
in situ imaging and flow cytometry of disaggregated tissue, the effects of environmental
exposures on both new mutation formation and clonal expansion can be revealed. One
application of these approaches is to use the FYDR mice to study the recombinogenic effects
of chemotherapeutic regimens, yielding valuable information about tissue specificity as well
as potential long term effects of such exposures. Given that HR is a critical process for
maintaining genomic integrity and for preventing DNA damage-induced cell death, in situ
detection of fluorescent recombinant cells provides a sensitive approach for studying the
potential genotoxic effects of pharmaceuticals and environmental exposures.
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Figure 3-1. FYDR system and analysis of pancreatic cells by in situ imaging. (A)
Arrangement of the FYDR recombination substrate: large arrows indicate expression
cassettes; yellow boxes show coding sequences; black boxes show positions of deleted
sequences (deletion sizes not to scale). An HR event between the two expression
cassettes can restore full-length EYFP coding sequence, resulting in a fluorescent cell.
Image depicts recombinant pancreatic cell within freshly excised tissue; bar, 10 pLm. Not
that the EYFP emission spectra largely overlaps with that of EGFP; this image has been
pseudocolored yellow. (B) Effects of aging on the frequency of recombinant cells in the
pancreas. Compiled images for juvenile (4 weeks old), adult (9 weeks old), and aged (64-
72 weeks old) FYDR mice. Examples of pancreata with the highest number of
recombinant foci for each cohort are shown. Images were collected at lx (bar, 1 cm)
using an EYFP filter (510-560 nm). The edge of the pancreatic tissue is outlined. This
figure was adapted from Wiktor-Brown, et al (51).
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Figure 3-2. MMC induced HR in mouse pancreata. (A) Recombinant foci per pancreas
detected by in situ image analysis for mock- and MMC-treated FYDR mice. (B)
Frequency of recombinant cells per million as determined by flow cytometry for mock-
and MMC-treated FYDR mice. * MMC-treated cohort is statistically significantly higher
than mock treated cohort (p < 0.05, Mann-Whitney). Medians are indicated by black bars.
Points on the x-axis indicate individual mice with no detectable recombinant cells. For
methods see Wiktor-Brown, et al (51).
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Figure 3-3. Inter-mouse variation in recombination and expression. (A) Recombinant
foci per pancreas detected by in situ image analysis in 9 week old male (n = 35) and
female (n =37) FYDR mice. Data combined from cohorts of untreated and mock-treated
mice. Medians are indicated by black bars. * Female cohort is statistically significantly
higher than male cohort (p < 0.05, Mann-Whitney). (B) Percentage of fluorescent
pancreatic cells as determined by flow cytometry from 9 week old male (n = 26) and
female (n = 28) FYDR-Rec mice. Data combined from cohorts of untreated and mock-
treated mice. Means are indicated by black bars. ** Female cohort is statistically
significantly higher than male cohort (p < 0.05, Student's t-test). (C) Average percentage
of fluorescent pancreatic cells as determined by flow cytometry from mock- (n = 10) and
MMC- treated (n = 10) FYDR-Rec mice (ratio of males to females is the same in mock-
and MMC-treated cohorts). Error bars indicate 1 standard deviation. For methods see
Wiktor-Brown, et al (51).
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Figure 3-4. Expression of EYFP in various tissues of female positive control FYDR-Rec
C57B1/6 and negative control WT C57B1/6 mice. (A) Pancreas (B) Kidney (C) Lung.
Histological images were collected at 10x. Left column: Positive control FYDR-Rec
tissue. Right column: Negative control WT C57B1/6 tissue. Top row: Fluorescence image
under EYFP filter (510-560 nm). Middle row: H&E stained section. Bottom row: Overlay
of H&E and fluorescence images. Brightness/contrast for EYFP filtered images was
optimized for each tissue and adjusted equivalently for positive control FYDR-Rec and
negative control WT C57B1/6 mice. EYFP fluorescence is pseudocolored.
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Chapter IV
Novel Integrated One- and Two-Photon Imaging Platform
Reveals Extent of Clonal Expansion in situ
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Chapter 4
4.1 Abstract
The clonal expansion of cells with mutations in genes that provide growth and
survival advantages is one of the pivotal first steps in cancer formation. To understand
the earliest stages of cellular transformation, a method to identify and analyze these pre-
malignant cells is needed. We have created a transgenic Fluorescent Yellow Direct
Repeat (FYDR) mouse in which cells that have undergone sequence rearrangements (via
a homologous recombination event) express a fluorescent protein, enabling the labeling
of phenotypically normal cells. In order to measure clonal expansion in situ, we have
integrated one- and two-photon microscopy to create a sensitive imaging system that
spans four orders of magnitude. This imaging platform rapidly identifies very rare
fluorescent cells within an entire mouse tissue (at the cm scale) and subsequently
provides 3D images of each fluorescent cell (at the micron scale). We applied these
techniques to study the effect of age on clonal expansion of fluorescent cells in the
pancreata of FYDR mice. Results show that as mice age, there is a significant increase in
the number of cells within fluorescent cell clusters, indicating that pancreatic cells can
clonally expand with age. This combination of mechanico-optical engineering
technologies with genetically engineered FYDR mice can be applied to study the effects
of genetic and environmental exposures on the risk of clonal expansion.
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4.2 Introduction
Cancer is caused by the accumulation of mutations within a single cell lineage.
This multi-step process occurs through successive rounds of clonal expansion and
selection of cells that have acquired mutations that confer growth advantages (1-4).
Analysis of tumors shows that key mutations in tumor suppressors and oncogenes are
often shared by most, if not all, malignant cells within the tumor (5-7). Although the
clonal expansion of pre-malignant cells is an important precursor to the development of
cancer, no methods had been developed to study clonal expansion within intact
histologically normal tissue.
Mutations that drive cancer development are often caused by DNA damage.
Human cells are subjected to thousands of DNA lesions each day (8), including a wide
variety of base modifications, cross-links and strand breaks. Of these DNA lesions,
double strand breaks (DSBs) are considered to be among the most dangerous, since a
single unrepaired DSB can result in the permanent loss of over 100 million base pairs of
genetic information (9), and misjoining of DSBs can lead to gross chromosomal
rearrangements (10). Mitotic homologous recombination (HR) is a critical pathway for
the accurate repair of potentially mutagenic DSBs (for review see (11)). During
recombinational repair, homologous sequences present on the sister chromatid or
homologous chromosome are used as templates for repair. In addition, HR provides the
only pathway for the accurate repair of DSBs that arise as a result of broken replication
forks (12-16).
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Given its key role in the repair of DSBs and broken replication forks, HR is
critical for maintaining genomic integrity. Indeed, inherited mutations in genes that
modulate HR (e.g. BLM (17), WRN (18), BRCA1 (19), BRCA2 (20)), are associated
with an increased risk of cancer (21, 22). In addition, environmental exposures to agents
that induce recombination events (e.g. ionizing radiation (23), sunlight (24) and
chemicals present in food (23)) also increase cancer risk (25-27), which is thought to be
at least partially due to the associated increased risk of tumor-promoting errors during the
recombinational repair of DNA damage. Thus, the frequency of HR events reflects both
the demand for repairing DBSs and the ability of cells to use HR as a repair pathway.
In order to study HR in vivo, we have developed transgenic Fluorescent Yellow
Direct Repeat (FYDR) mice, in which a HR event at an integrated transgene results in
expression of a fluorescent protein (28). In FYDR mice, cells harboring recombined
DNA can be detected within intact pancreata (29). Age is a key risk factor for pancreatic
cancer (30); therefore, we studied the effect of aging on HR in the pancreas (29). Our
previous work shows that recombinant cells accumulate in the pancreas of FYDR mice
with age and that this accumulation results from both de novo recombination events as
well as clonal expansion of previously existing recombinant cells. Although clonal
expansion was estimated using traditional epifluorescence microscopy, it was not
possible to determine the number of recombinant cells per focus using this approach.
Thus, the extent of clonal expansion, an important precursor to tumor formation, could
not be quantified.
Traditional epifluorescence microscopy uses one-photon for excitation of
fluorophores. In a spatially uniform fluorescent sample, equal fluorescence intensities are
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contributed from each z-section above and below the focal plane (31). Thus, within a
thick sample, the boundaries of fluorescent structures are difficult to resolve when the
emitted light is diffracted by tissue between the fluorescent object and the surface (i.e.,
the light is scattered by out-of-focus tissue). To overcome this problem, Denk et al.,
developed two-photon microscopy wherein chromophores can be excited only at a region
of high temporal and spatial concentration of photons (32). This is achieved by the
simultaneous absorption of two-photons, each having half the energy needed for the
excitation transition (32, 33). Thus, only molecules at the focal point are excited,
reducing photobleaching and phototoxicity, and enabling higher resolution of fluorescent
images. While two-photon microscopy offers increased resolution of images, it is most
effective for imaging on micrometer length-scales. Consequently, analysis of significant
tissue volumes (e.g., > 1 cm3) is prohibitively slow, making this a suboptimal approach
for studies of rare fluorescent objects within a tissue.
Here, we have combined the speed of traditional fluorescence microscopy with
the resolution of two-photon microscopy to create a quantitative method for the analysis
of fluorescent foci within intact tissue. Specifically, in these studies using FYDR mice,
rapid two-dimensional fluorescence imaging ofpancreata enables the identification and
mapping of recombinant foci within the tissue. Subsequent optical sectioning of
recombinant foci using two-photon microscopy enables the quantification of cells within
each focus with minimal damage to the tissue and without distortion of cell-cell
relationships. The integrated one- and two-photon imaging platforms were then applied to
study the effect of aging on HR in the pancreas. Results reveal that as mice age,
recombinant pancreatic cells undergo clonal expansion, in some cases to an unexpected
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degree, resulting in a significant increase in the overall frequency of cells harboring DNA
sequence rearrangements.
4.3 Materials and Methods
One-Photon Imaging
Female C57BL/6 FYDR mice (28) were IP injected with 0.04 mg/g of body
weight of 5 mg/ml Hoechst 33342 (Sigma) in phosphate buffered saline. Twenty minutes
after injection, pancreata were isolated and placed in ice-cold PBS containing 0.01%
soybean trypsin inhibitor (Sigma). Whole pancreata were pressed between glass slides
separated by 0.5 mm spacers. Sequential images were collected in black and white using
a 1.25x objective, a 532 nm laser for EYFP excitation, and a fixed aperture time. Images
were compiled to cover the entire visible surface area. Foci positions were mapped using
an automated x-y stage positioner. At each x-y coordinate, sequential 2D two-photon
images are collected.
Two-Photon Imaging
Procedure for collecting two-photon images is described elsewhere (Kwon et al.,
in preparation)
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4.4 Results
Development of Two-Photon Imaging for Analysis of Recombinant Foci
To study homologous recombination in vivo, we developed FYDR mice, which
carry a direct repeat recombination substrate that contains two differently mutated copies
of the coding sequence for enhanced yellow fluorescent protein (EYFP). An HR event
can restore full-length EYFP coding sequence, resulting in the appearance of fluorescent
cells (28) (Fig. 4-1A). To identify recombinant cells within intact pancreata of FYDR
mice, previously we developed an in situ imaging method using traditional
epifluorescence microscopy (29). Briefly, FYDR pancreata are imaged using filters
specific for Hoechst-stained nuclei (Fig. 4-1B, left) and EYFP (Fig. 4-1B, middle).
Overlaying these images shows that recombinant foci can be directly detected within
intact pancreata (Fig. 4-1B, right).
Using epifluorescence microscopy, when a recombinant focus is present on the
surface of the pancreas, the boundaries are distinct and it is possible to estimate the
number of cells within the focus (Fig. 4-1C, left). However, for foci located below the
surface, the scattering of emitted fluorescence prevents identification of specific cell
boundaries, making it impossible to quantify the number of cells per focus (Fig. 4-1 C,
right). Due to the limitation of traditional epifluorescence microscopy to obtain high
resolution images of fluorescent foci, a two-photon method to create images of cross-
sections of recombinant foci was developed. To image recombinant foci by two-photon
microscopy, a low energy laser is used to excite Hoechst stained nuclei and EYFP
containing cytoplasm. By overlaying images taken under the two filters, the number of
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individual cells (-20-30 lm in diameter) contained within a single cross-section of the
recombinant focus can be quantified. These two-dimensional images show that two-
photon microscopy can provide high resolution images of fluorescent recombinant foci at
a depth of up to 70 pm within pancreata of FYDR mice.
To determine the extent to which one-photon microscopy distorts the true size of
recombinant foci, a comparative analysis was performed for multiple foci collected by
both epifluorescence and two-photon microscopy. A fluorescent focus that appears large
by epifluorescence only contains a single cell (Fig. 4-2A), while a focus that appears
small by epifluorescence contains multiple cells (Fig. 4-2B). The discrepancies between
foci sizes as seen by epifluorescence and two-photon microscopies may be due to focus
depth and brightness. First, the depth of a focus may affect its size when imaged using
epifluorescence microscopy since the diffraction of light emanating from fluorescent
objects located deep in a tissue can lead to the appearance of a larger size relative to the
same object located on the surface. In addition, the intensity of fluorescence from cells
may affect apparent focus size by epifluorescence microscopy with brighter foci having
an apparently larger size than dimmer foci. Thus, while epifluorescence microscopy
enables the rapid identification of recombinant foci within an entire pancreas, two-photon
imaging provides a more accurate method for in situ quantification of the number of cells
within a single recombinant focus.
Integrating One- and Two-Photon Imaging Platforms
While two-photon imaging is effective for measuring the number of cells per
recombinant focus, analyzing the entire surface of a pancreas (-2.5 cm2) would take at
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least -20 hours. Therefore, to study multiple mice under different conditions, we created
a system that enables rapid data collection for both the frequency of recombinant foci and
the number of cells within foci. For each sample, the pancreas is uniformly compressed to
a thickness of 0.5 mm and images are taken using an epifluorescence microscopy with a
low powered objective to cover the entire surface area. Fluorescent recombinant foci are
identified and their x,y coordinates are mapped within the composite images.
Subsequently, using two-photon microscopy, centering upon the coordinates of the
previously mapped positions, multiple sequential z-planes are acquired through a
maximum thickness of 70 pm for each focus. The images are then deconvoluted to
produce a 3D reconstruction of the focus, differentiating Hoechst-stained nuclei and
EYFP. Thus, the combination of epifluorescence and two-photon microscopy enables the
identification and analysis of recombinant foci over the entire surface of a pancreas.
The Frequency and the Size of Fluorescent Foci Increase With Age
In order to study the effect of aging on recombinant cell frequency, we analyzed
pancreata from two age groups, 'juvenile' (4-6 weeks old) and 'aged' (74-83 weeks old).
Composite epifluorescence images show that both the frequency and the apparent sizes of
the foci appear to increase with age, which is consistent with our previous studies (see
Wiktor-Brown et. al. (29)). Further analysis of the foci using two-photon microscopy
reveals that the number of cells within recombinant foci varies within each age cohort
(Fig. 4-3). Of the foci analyzed in pancreata of juvenile mice, the largest recombinant
focus contained five cells. In contrast, -54% of recombinant foci in aged mice contain
more than five cells, with one focus containing at least 68 cells. Overall, from juvenile to
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aged mice, the median number of cells per focus increases from two to six cells. Given
that expression of the FYDR substrate is not statistically significantly different between
the two cohorts (data not shown), these data indicate that as mice age, recombinant
pancreatic cells can clonally expand.
It is formally possible that the increase in the number of cells per recombinant
focus is the result of multiple independent recombination events occurring in neighboring
cells. However, since the frequency of recombinant cells in the pancreas is ~5 per million
(29), the probability that two adjacent recombinant cells occurred from independent
events is roughly 1/1010 (assuming that each cell touches -10 neighbors), making it
virtually impossible that multiple adjacent recombinant cells in large foci occurred
independently. Therefore, recombinant foci containing multiple cells are most likely the
result of clonal expansion and not independent recombination events in neighboring cells.
4.5 Discussion
For some tumors, it may take 20-40 years from the initial formation of a cancer
progenitor cell to the appearance of a detectable tumor (34-37). During this time, the
population of pre-cancerous cells can increase as the result of clonal expansion (3).
However, these clonal cell populations can appear to be phenotypically normal, even
though they have acquired mutations in tumor suppressors or oncogenes that may provide
a survival and proliferative advantage. The ability to detect clonal expansion in situ
within histologically normal tissue enables the identification of these clonal cell
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populations, and studying these cells may provide insights into of the earliest stages of
cellular transformation, prior to the clinical appearance of a tumor.
Two-dimensional epifluorescence microscopy enables the rapid, low-resolution
identification of rare fluorescently labeled cells over the entire surface of an intact tissue.
Three-dimensional two-photon microscopy provides high-resolution imaging on a
micrometer scale to quantify the number of cells contained within fluorescent foci. By
combining these approaches, rare fluorescent cells can be analyzed from the tissue (cm
scale) to the single cell (pm scale). A number of imaging techniques are available for the
gross analysis of tissues (e.g., MRI, CT); however, these cannot provide resolution on the
single cell level. Other methods that have been used to obtain high resolution 3D images
of tissues (e.g., physical serial tissue sectioning (38) and confocal microscopy (Pawley
1995)) have multiple limitations including the length of time to collect data, distortion of
cell morphology and phototoxicity. In contrast, optical sectioning by 3D two-photon
microscopy enables cells to be studied within their normal physiological context,
obtaining accurate information regarding cell-cell relationships in a relatively short
amount of time. Thus, the integration of one- and two-photon microscopy allows the
rapid collection of data for not only the total number of fluorescent cell clusters within an
intact tissue but also the number of cells within each cluster, over a range of length-scales
that span >4 orders of magnitude.
HR events are an important class of mutations that are known to promote cancer
(11). Here, we have applied the combination of one- and two-photon imaging to study
HR events in the pancreata of FYDR mice in situ. Most other techniques for studying
mutations require tissue disaggregation followed by analysis of either cultured primary
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cells or genomic DNA (e.g., RMC, Aprt, Tk, Big Blue, Muta Mouse, GptA)(39-42), thus
limiting information about the clonal relationship among mutant cells. In contrast, the
techniques described here enable the quantification of cells within recombinant foci,
providing information about the extent of clonal expansion. In addition, being able to
detect a single fluorescent cell within an entire pancreas (-3x107 cells (43)), makes this
imaging technique one of the most sensitive methods for detecting rare DNA sequence
changes. Finally, we have previously shown that because independent mutation events
(i.e., independent recombinant foci) can be distinguished, in situ imaging is more
sensitive than tissue disaggregation for determining environmentally induced mutations
in adult tissues (44). Taken together, integrated one- and two-photon imaging provides a
highly sensitive method for detecting and analyzing cells that contain small sequence
rearrangements within intact tissues.
Inherited mutations in several genes known modulate HR (i.e., BRCA1 (45),
BRCA2 (46), and FANCC (47)) increase the risk of pancreatic cancer, suggesting that
HR plays an important role in maintaining genomic integrity in the pancreas. Using the
FYDR mice, we have previously shown that as mice age, recombinant cells accumulate
in the pancreas in part due to de novo recombination events (29), suggesting that HR
remains an active repair pathway in the pancreata of adult animals. Although HR is
generally error-free, recombination between misaligned sequences can cause insertions,
deletions, and translocations that promote cancer. In fact, the FYDR mice specifically
detect sequence rearrangements that result from misalignments at a repeat sequence (for
mechanisms, see (48)). Although the FYDR mice detect HR only at one specific locus,
DNA damage and repair are not confined to this locus, and misalignments can occur
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spontaneously throughout the genome at natural repeat sequences (-40% of the genome
is comprised of repeat elements (49)). The susceptibility of cells to both new mutation
formation and clonal expansion of pre-existing mutant cells are important in
carcinogenesis. Here, results shows that the number of cells per recombinant focus
increases with age, indicating that clonal expansion of recombinant cells within existing
foci significantly contributes to the accumulation of recombinant cells within the
pancreas. By applying this new imaging platform to the FYDR mice, it is now possible
not only to detect the accumulation of cells harboring rare sequence rearrangements but
also to study the extent to which conditions foster clonal expansion of such mutant cells.
Within the FYDR pancreas, recombinant cells are most likely acinar cells. Acinar
cells are part of the exocrine pancreas and secrete hydrolytic enzymes into the duodenum
that aid in digestion. The secretory unit within the exocrine pancreas is a grape-like
structure called an acinus, which contains ten to forty acinar cells that secrete enzymes
into a system of epithelial ducts (50). Acinar cells may play an important role in tumor
formation. Evidence suggests that acinar to ductal transdifferentation can occur in vivo
and in vitro, leading to the formation of pancreatic intraepithelial neoplasias and
pancreatic ductal adenocarcinoma (51-57). In the adult pancreas, acinar cells exhibit
extremely low levels of proliferation, with -1% of cells in S phase (58). However, in
response to damage, such as pancreatectomy or chemical injury, proliferation of acinar
cells is stimulated (59, 60). Furthermore, the half-life of acinar cells in the mouse
pancreas has been estimated to be at least 70 days (61-63), indicating that acinar cells
persist within the pancreas for long periods of time. In this study, we observed one
recombinant focus from an aged mouse that contained 68 cells, indicating that significant
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clonal expansion (at least seven population doublings) can occur within the acinar cell
compartment of the adult pancreas. These data provide new information regarding the
proliferative capacity of adult acinar cells in vivo. It will be interesting to further apply
these techniques to learn more about how injury affects clonal expansion of pancreatic
cells.
Measuring HR events provides information on both the formation of DSBs and
the ability of cells to use HR as a repair pathway. Here, we have shown that by
combining 2D epifluorescence microscopy and 3D two-photon microscopy, recombinant
cells can be detected and quantified within intact FYDR pancreata. By providing
information regarding both the induction of de novo recombination events as well as the
clonal expansion of recombinant cells, the integration of these techniques can be applied
to study the long term effects of environmental exposures and genetic alterations. Given
the importance of clonal expansion as a precursor to tumor formation, these techniques
provide new avenues to learn about the earliest stages of cellular transformation. Finally,
this new imaging platform can be applied to analyze any cells that can be labeled with
fluorescence (i.e., putative adult somatic stem cells), enabling the detection of these rare
cells within intact tissue and the study of their propensity to clonally expand.
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Figure 4-1. FYDR system and detection of recombinant cells by epifluorescence
microscopy in mouse pancreata. (A) Arrangement of the FYDR recombination substrate:
large arrows indicate expression cassettes; yellow boxes show coding sequences; black
boxes show positions of deleted sequences (deletion sizes not to scale). An HR event
between the two expression cassettes can restore full-length EYFP coding sequence,
resulting in a fluorescent cell. (B) In situ images of a freshly excised FYDR pancreas
taken at lx (scale bar = 1 mm). Nuclei are stained with Hoechst 33324. Left: UV- (420
nm) filtered image to detect nuclei. Middle: EYFP- (510-560 nm) filtered image to detect
recombinant foci. Overlay of UV- and EYFP-filtered images. (C) Distortion of
recombinant cell boundaries by epifluorescence microscopy taken at 40x (scale bar = 10
gm). Left: recombinant focus located on the tissue surface. Right: recombinant focus
located below the surface shows diffraction through cells.
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Figure 4-2. Comparison of apparent foci sizes by epifluorescence and two-photon
microscopies. (A) A fluorescent focus that appears large by epifluorescence microscopy
only contains a single cell as determined by two-photon microscopy (inset). (B) A
fluorescent focus that appears small by epifluorescence contains multiple cells as
determined by two-photon microscopy (inset).
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Figure 4-3. Effect of age on the number of cells within recomabinant foci. Number of
cells per recombinant focus for (A) juvenile (n = 79 foci) and (B) aged (n = 68 foci)
FYDR mice. Each point represents one focus. Medians are indicated by black bars.
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Chapter 5
5.1 Abstract
Mitotic homologous recombination (HR) is a critical pathway for the accurate
repair of DNA double strand breaks (DSBs) and broken replication forks. The misrepair
of DSBs can lead to large scale sequence rearrangements, and an increase in these types
of mutations is often seen with age, suggesting that the inability to accurately repair
DSBs is an important contributor to aging. To learn more about the effect of aging on the
repair of DSBs by HR, we used Fluorescent Yellow Direct Repeat (FYDR) mice in
which an HR event in a transgene yields a fluorescent phenotype. Here, we show tissue-
specific differences in the accumulation of recombinant cells with age. Pancreas shows a
dramatic increase in recombinant cell frequency with age, whereas skin shows no
increase in vivo. In vitro studies indicate that juvenile and aged primary fibroblasts are
similarly able to undergo HR in response to endogenous and exogenous DNA damage,
suggesting that the lack of accumulation of recombinant cells in the skin is most likely
not due to an inability to undergo de novo HR events. We propose that tissue-specific
differences in the accumulation of recombinant cells with age results from differences in
the ability of recombinant cells to persist and clonally expand within the tissue.
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5.2 Introduction
The accumulation of somatic mutations is considered to be a major cause of aging
(1). Mutations are believed to accumulate with age due to a combination of increased
levels of endogenous DNA damaging agents, such as reactive oxygen species (2), and
decreased efficiency and fidelity of DNA repair (3-7). Double strand breaks (DSBs) are
considered to be among the most toxic and mutagenic lesions that mammalian cells
experience. In the context of aging, the steady-state levels of DNA DSBs have been
shown to increase with age (8, 9). Furthermore, the improper repair of DSBs can lead to
large scale genomic sequence rearrangements, such as translocations, insertions, and
deletions (10), and an increased frequency of such rearrangements is often observed in
aged cells (11-15). Consistent with these findings, it has also been shown that
deficiencies in the ability to repair DSBs cause accelerated aging (16). Together, these
data suggest a model in which DSBs and their repair are critical factors in the aging
process.
Mammalian cells use two main pathways for the repair of DSBs: non-homologous
end joining (NHEJ) and homologous recombination (HR). NHEJ directly rejoins DSBs in
a sequence independent manner, often resulting in small sequence alterations (17, 18). In
contrast, HR uses homologous sequences present on the sister chromatid or homologous
chromosome as templates for repair, enabling the repair of DSBs with high fidelity (10).
NHEJ is the preferred pathway for the repair of DSBs during Go/G 1 phases of the cell
cycle, whereas HR is important during late S/G2 (19). Although HR is generally error free,
exchanges between misaligned sequences can lead to insertions, deletions, translocations,
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and loss of heterozygosity (LOH). Since over 40% of the genome is comprised of
repeated elements (20), during Go/G 1, NHEJ is preferred to minimize deleterious
rearrangements (21). In contrast, when a sister chromatid is present during S phase, HR is
preferred since it plays an essential role in the repair of DSBs that arise as a result of
replication fork breakdown (i.e., replication fork encounter with a blocking DNA lesion
or a single strand gap (22-26)). Indeed, HR is the only DNA repair pathway that can
accurately reinsert the broken DNA end to restart the replication fork (10). If DSBs at
broken forks are instead acted upon by NHEJ, ends from independent loci can be joined,
which will inevitably lead to large scale sequence rearrangements. Thus, in order to
prevent mutation formation, it is critical that cells initiate the appropriate DSB repair
pathway.
Germline mutations in genes that modulate DSB repair cause premature aging
syndromes. For example, Werner syndrome is caused by a mutation in the RecQ-like
DNA helicase WRN (27, 28). WRN is believed to play an important role in the resolution
of HR intermediates (29, 30), and loss of function of WRN is associated with an
increased frequency of deleterious recombination events (31-33). In addition, heritable
mutations in ATM, a protein that plays a critical role in initiating DSB repair (34), result
in ataxia telangiectasia, a disease that is associated with symptoms of premature aging
(16). Interestingly, ATM' - cells show an increased frequency of HR and are particularly
susceptible to error-prone HR (35-38). Finally, mice with germline mutations in Ku80
(Ku86), an integral protein in NHEJ, exhibit an accelerated aging phenotype (39).
Together, these results show that defects in DSB repair can promote aging.
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Because of its potentially pivotal role in suppressing aging and age-related
diseases, there is great interest in understanding how DSB repair by HR changes in
somatic cells with age. To measure the accumulation of cells harboring recombined DNA
during aging, LOH has been analyzed (40, 41). Since LOH can be caused by multiple
mechanisms, careful analysis of DNA must be done in order to reveal the fraction of
events resulting from HR. Using such analyses, it has been shown that HR is responsible
for a significant fraction of LOH events in both lymphocytes and kidney cells that
accumulate with increasing age (40, 41), suggesting that HR contributes significantly to
DNA rearrangements that occur during aging. For technical reasons, little is known about
the importance of HR in other cells types. In particular, unless a cell can be cultured ex
vivo, the accumulation of recombinant cells cannot be studied using these approaches.
In addition to these studies of HR and LOH, the accumulation of point mutations
in various tissues has also been measured by using mouse models for mutation detection
(42-45). Intriguingly, the effect of age on mutation frequency appears to be strongly
tissue-dependent, and differences in mutation accumulation do not correlate with
proliferation of cells within the tissue. For example, in tissues with low proliferation rates,
an increase in mutant cell frequency with age is seen in the heart (44, 45) but not in the
brain (42-44, 46). In addition, tissues that exhibit high proliferation rates, mutant cell
frequency increases in the small intestine (45, 47) but not in the testis (42, 44, 48). Thus,
although the accumulation of mutations differs among tissues, the reasons for these
differences are not yet known.
Here, we set out to investigate the effects of aging on the frequency of HR events
in two different tissue types in vivo. To study recombination in vivo, we developed the
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Fluorescent Yellow Direct Repeat (FYDR) mice, in which an HR event at an integrated
transgene yields a fluorescent cell (49). A comparison of pancreatic and skin tissues
shows that while recombinant cells accumulate in the pancreas with age, the frequency of
recombinant cells in skin does not change. Previously, we had shown that the
accumulation of recombinant cells in aged pancreata results not only from de novo
recombination events but also from clonal expansion of existing recombinant cells (50).
To determine if the lack of accumulation in skin results from a decrease in the demand
for HR with age, we analyzed primary fibroblasts from FYDR mice in vitro. Neither the
spontaneous rate of HR nor the ability of cells to use HR in response to an exogenous
recombinogen change with age, suggesting that fibroblasts within aged skin are able to
undergo de novo recombination events in vivo. Thus, the lack of accumulation of
recombinant cells in aged skin may be due to the absence of extensive clonal expansion
in skin fibroblasts with age.
5.3 Materials and Methods
Animals
C57BL/6 FYDR were described previously (49). Positive control FYDR-
Recombined (FYDR-Rec) mice arose spontaneously from an HR event in a FYDR
parental gamete, and all cells carry the full-length EYFP coding sequence (51). FYDR
cohorts had equal ratios of males to females. Controls were sex and age matched, except
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the aged negative control C57BL/6 were 47-85 weeks old and the aged positive control
FYDR-Rec mice were 52-68 weeks old.
Isolation of Ear Fibroblasts and Ventral Skin Cells
Ventral skin or ears were isolated, minced, and incubated at 370C in 4 mg/ml
collagenase/dispase (Roche Applied Sciences). After 1 hour, two volumes of fibroblast
medium was added [DMEM, 15% FBS, 100 units/ml penicillin, 100 pg/ml streptomycin,
5 pg/ml amphotericin B (Sigma)]. After 24 hours at 370C and 5% CO 2, cells were
triturated, filtered (70-pm mesh; Falcon), and analyzed by flow cytometry (ventral skin
cells) or seeded into dishes (ear fibroblasts). For all in vitro studies, primary ear
fibroblasts were isolated from 5 juvenile (4 weeks old) and 5 aged (62-89 weeks old)
female FYDR mice in parallel. After pooling cells from mice within each cohort, -1
million cells were analyzed by flow cytometry to determine the initial frequency of
recombinant cells within each age group. The remaining cells were plated to for in vitro
studies.
Flow Cytometry
Pancreatic cells were disaggregated as described previously (50). Disaggregated
pancreatic or skin cells were pelleted and resuspended in 350 l OptiMEM (Invitrogen),
filtered (35 plm), and analyzed with a Becton Dickinson FACScan flow cytometer
(excitation 488 nm, argon laser). Live cells were gated by using forward and side scatter.
On average, 1 million cells were analyzed per sample for flow cytometry.
136
Calculation of Recombination Cell Frequency and Rate in Primary Fibroblasts
Using pooled primary ear fibroblasts isolated from 5 juvenile and 5 aged FYDR
mice, 3 rate experiments were plated in parallel for each age cohort. For each rate
experiment, -104 cells were seeded into 24 independent cultures. Cultures were expanded
and analyzed by flow cytometry once the density reached -106 cells per well. The
method ofpo was used to determine the rate of recombination per cell division as
described (52, 53). Rate experiments were repeated with fibroblasts from different
cohorts of mice 3 times. For frequency analysis, the final frequencies for each culture of
the rate experiment were averaged.
Comet assay
Alkaline comet assay experiments were performed using pooled primary ear
fibroblasts isolated from 5 juvenile and 5 aged FYDR mice. Two independent
experiments with 3 replicate slides per sample were carried out at dim light using a
commercially available comet assay kit according to the manufacturer's protocol
(Trevigen, Gaithersburg, MD). Briefly, cells were trypsinized, rinsed with ice cold Ca++
and Mg++ free PBS and counted. 2x10 4 cells per slide were then suspended in 80 pl of 1%
molten low melting point agarose and pipetted onto comet assay slides (Trevigen). After
incubation at 40C for 30 min slides were immersed in pre-chilled lysis solution
(Trevigen) for 60min at 40C, rinsed with ice cold PBS and transferred for a 40 min
incubation in an alkaline solution (pH>13) at room temperature allowing DNA
unwinding. Next, slides were subjected to electrophoresis at 30V for 30min followed by
rinsing 5min with 70% ethanol. Slides were kept in a moist chamber overnight at 40C,
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stained with ethidium bromide and analyzed on a Nikon Fluorescence microscope using
Komet 5.5 Software (Andor Technologies, South Windsor, CT). 99 cells per slide were
quantified for percent comet tail DNA and Olive tail moment.
SCE analysis
Primary ear fibroblasts from 5 juvenile and 5 aged FYDR mice were pooled and
seeded at 2 x 105 cells per well. After 24 hours, 10tM BrdU was added to the culture
media. Cells were harvested after undergoing two population doublings and analyzed for
SCE frequency as previously described (54). SCEs were counted in a blinded fashion
from 2 independent experiments with each experiment containing cells combined from 5
mice per cohort.
Quantification of DNA Damage-Induced Recombination
Primary ear fibroblasts from 5 juvenile and 5 aged FYDR mice were pooled and
seeded at 0.5 x 106 cells per 100 mm dish. After 24 hours, triplicate or quadruplicate
samples were exposed to 0.5 pg/ml mitomycin-C (MMC) for 1 hour. After 72 hours,
samples were analyzed by flow cytometry. Population growth was determined from the
number of viable cells per dish. Experiments were repeated with fibroblasts from
different cohorts of mice 3 times.
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5.4 Results
Comparison of Spontaneous Recombinant Cell Frequency in Pancreatic and
Cutaneous Tissues
To study HR in vivo, we previously developed FYDR mice that carry a direct
repeat recombination substrate containing two differently mutated copies of the coding
sequence for enhanced yellow fluorescent protein (EYFP). An HR event can restore full
length EYFP coding sequence, thus yielding a fluorescent cell (Fig. 5-1A). One method
for determining the in vivo frequency of recombinant cells is to analyze disaggregated
tissue by flow cytometry (50, 55). Briefly, we compared fluorescence intensities in
disaggregated skin from negative control and positive control (FYDR-Recombined (51))
mice and established a region (R2) that excludes negative control cells (Fig. 5-1B). Over
21 million skin cells from 20 negative control mice were analyzed by flow cytometry and
no cells appeared in the R2 region, indicating an extremely low background.
The distribution of spontaneous recombinant cell frequencies in pancreatic tissue
from 100 mice aged 4-10 weeks was previously established (Fig. 5-1C and (50)). To
compare homologous recombination between pancreas and skin, skin from 100 mice
aged 4-10 weeks was similarly analyzed (Fig. 5-1C). Although recombinant cell
frequency is variable among mice for both tissues, the median recombinant cell
frequency is statistically significantly higher for pancreas than for skin (five and one,
respectively). Additionally, analysis of independent mice shows that -20% of mice
contained more than 20 recombinant cells per million in the pancreas, as compared to 4%
for skin, suggesting that the distribution of recombinant cell frequencies in mice differs
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between tissues. High spontaneous frequencies of recombinant cells observed in some
samples may result from an early HR event followed by clonal expansion of the resulting
fluorescent cell. These data raise the possibility that fluorescent recombinant cells within
the pancreas may be more likely to clonally expand than those contained within the skin.
It is formally possible that differences in recombinant cell frequencies for
pancreatic versus skin tissues may be due to differences in the expression levels of the
FYDR transgene. Clearly, if EYFP is expressed at lower levels, it will be more difficult to
detect recombinant cells. To determine if the increased frequency of recombinant cells in
pancreatic tissue is due to increased EYFP expression, we analyzed pancreatic and skin
tissues from positive control mice that carry the full-length EYFP coding sequence in
every cell (51). EYFP expression is statistically significantly higher in pancreatic (-52%)
versus skin (~30%) tissues (Fig. 5-1D). Because in positive control mice the EYFP
coding sequence is expressed under an identical promoter and at the same locus as the
FYDR recombination substrate, it is likely that there is a similar nearly 2-fold higher
expression in pancreatic tissue of the FYDR mice as well. A 2-fold higher level of
expression in the pancreas compared to skin partially explains the observation that there
is a higher median frequency of recombinant pancreatic cells compared to skin cells.
However, the difference in EYFP expression is not sufficient to account for the 5-fold
higher median recombinant cell frequency in pancreatic compared to skin tissues, nor
does it explain differences in the distribution of recombinant cell frequencies in each
tissue type.
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Tissue-Specific Effect of Aging on Recombinant Cell Frequency
The observation that a larger proportion of the mice show very high frequencies
of recombinant cells in the pancreas compared to skin raises the possibility that
recombinant cells in the pancreas have the ability to persist and clonally expand, while
those in the skin do not. To explore the effects of aging, recombinant cells were
quantified in pancreas and skin from two different age groups: 'juvenile' (4 weeks old)
and 'aged' (62-89 weeks old). For pancreatic tissue, the median frequency of
recombinant pancreatic cells increased -23 fold from juvenile to aged mice (Fig. 5-2A;
(50)). Given that there is no statistically significant difference in EYFP expression with
age in pancreatic cells (Fig. 5-2B), these data indicate that recombinant cells accumulate
in the pancreas with age. For skin tissue, analysis of the recombinant cell frequency
shows that the median is virtually identical between the juvenile and aged cohorts (Fig. 5-
2C). Comparison of EYFP expression in skin with age shows no statistically significant
difference between juvenile and aged mice (Fig. 5-2D). Thus, unlike in pancreatic tissue,
recombinant fluorescent cells do not accumulate in cutaneous tissue with age.
Effect of Age on HR in Cultured Primary Fibroblasts
Previous studies (50) show that accumulation of recombinant cells in the pancreas
is caused by both de novo recombination events and clonal expansion. Therefore, the fact
that recombinant cells do not accumulate in skin can be explained by either a lack of de
novo recombination events, a lack of persistence of cells that harbor recombined DNA, or
a lack of clonal expansion with age (or some combination of these factors). A lack of de
novo recombination events may result from a decrease in the rate of HR with age. To test
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this hypothesis, primary fibroblasts from juvenile and aged mice were cultured in vitro.
Expansion of cells for -7 population doublings shows that recombinant cell frequency in
cultures of both juvenile and aged cells increases, suggesting that HR is an active repair
process in dividing cells in vitro for both age groups (Fig 5-3A). Furthermore, we
estimated the rate of recombination in juvenile versus aged primary fibroblasts using the
po method (52, 53). We found that there is no statistically significant difference in the rate
of recombination between juvenile and aged cells (Fig. 5-3B). To determine if differences
in the EYFP expression levels exist, fibroblasts from juvenile and aged positive control
mice were cultured in parallel with rate experiments. Results show that there is no
significant difference in EYFP expression with age in vitro (data not shown), indicating
that differences in EYFP expression do not affect the apparent rates of HR. These data
suggest that juvenile and aged cells are comparable in their HR capacity.
The rate of HR can depend on the site of integration of a recombination substrate
(56). To determine if the relationship between the rate of recombination in juvenile and
aged cells is genome-wide, the frequency of HR events was measured using an
independent method; namely, sister chromatid exchange (SCE) analysis. For SCE
analysis, sister chromatids are differentially stained by culturing cells in the presence of
the base analog 5-bromo-2'-deoxyuridine (BrdU) for two cell divisions. Recombination
events that occur during these two replication cycles can be visualized in metaphase
spreads (Fig. 5-3C). Blinded analysis of SCEs from juvenile and aged cells shows no
statistical difference in the frequency of SCEs (Fig. 5-3D). Thus, since the rate of HR, as
measured at the FYDR locus and by SCE analysis, is not statistically different between
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juvenile and aged fibroblasts, the lack of accumulation of recombinant cells in skin with
age does not result from a suppression of HR.
DNA damage is known to induce HR, and therefore the rate of HR depends upon
the amount of damage present within cells. To determine if the lack of accumulation of
recombinant cells in the skin might be due to diminished pressure to use HR, we assessed
the amount of DNA damage within primary fibroblasts. For these studies, we evaluated
the levels of single-strand breaks and alkali sensitive sites in juvenile and aged cells using
the Comet assay under alkaline conditions. The average olive tail moment and percent
tail DNA are two different ways to analyze the amount of DNA damage from Comet data.
The averages for both olive tail moment (Fig. 5-3E) and percent tail DNA (Fig. 5-3F) are
not statistically different between juvenile and aged fibroblasts, suggesting that the
number of spontaneous single-strand breaks and alkali sensitive sites does not differ
between these age cohorts. Therefore, we conclude that it is unlikely that differences in
spontaneous levels of DNA damage explain the lack of accumulation of recombinant
cells in skin.
Effect of Age on DNA Damage-Induced Recombination
Although fibroblasts cultured from juvenile and aged mice are similarly able to
recombine in the presence of spontaneous damage, the ability to respond to exogenous
DNA damage may change with age. To determine if aged cells are differentially sensitive
to exogenous DNA damage, juvenile and aged fibroblasts were treated in vitro with the
cross-linking agent and potent recombinogen mitomycin-C (MMC). Cell proliferation
and recombinant cell frequency were analyzed 72 hours post mock- or MMC-treatment.
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Compared to mock-treated cells, juvenile and aged cells treated with MMC exhibit
similar decreases in cell densities (Fig. 5-4A), indicating that growth inhibition following
MMC treatment is similar in both age cohorts. For both juvenile and aged fibroblasts,
analysis of recombinant cell frequency by flow cytometry shows a statistically significant
increase in the frequency of recombinant cells for MMC-treated as compared to mock-
treated cells (Fig. 5-4B). However, there is no statistically significant difference in the
magnitude of induction between juvenile and aged cells, suggesting that juvenile and
aged fibroblasts are similarly able to respond to exogenous DNA damage.
5.5 Discussion
Many human progeroid syndromes, such as Werner Syndrome, Ataxia
Telangiectasia, Cockayne Syndrome, and Trichothiodystrophy, are caused by defects in
proteins that sense or repair DNA damage (16), indicating that the inability to accurately
repair DNA damage contributes to aging. It is hypothesized that during the aging process,
mutations accumulate within cells, causing diminished cell viability or capacity to carry
out normal functions (1). Over time, the number of mutant cells within a tissue can
increase, resulting in an overall reduction of tissue function. An increase in mutant cell
frequency with age can result from a combination of multiple factors, including an
increase in DNA damage levels, a decrease in DNA repair capacity and/or an increase in
the persistence or clonal expansion of mutant cells within a tissue. In these studies, we
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analyzed the relative contribution of these factors to recombinant cell accumulation with
age in pancreas and skin.
HR events are an important class of mutations that are believed to contribute to
the aging process (40, 41). Here, using the FYDR mice, we have shown that the
frequency of recombinant cells within pancreatic tissue increases -23-fold with age,
while in skin tissue there is no accumulation. Other mouse models, including Big Blue
(42, 43), Muta Mouse (44), and LacZ (45), have been used to examine changes in
mutation frequency with age in various tissues. Consistent with our data, the effect of age
on mutation frequency appears to be strongly tissue-dependent. Although none of these
studies have reported mutation frequency in the pancreas, increases in mutant cell
frequency with age have been shown in a number of other gastro-intestinal tissues
including the liver and small intestine (42-47). Interestingly, however, no tissues have
shown such a dramatic increase in mutant cell frequency with age as we see in the
pancreas. In terms of the skin, one study showed a slight increase (-1.5-fold) in mutant
cell frequency with age, although the cell type examined was not described (44). Thus,
little or no increase in mutant cell frequency is observed in skin with age, which is in
sharp contrast to the large increase observed in pancreas and other gastrointestinal tissues.
We and others have found that the magnitude of the increase in mutant frequency
with age did not correlate with cellular proliferation within the tissue. For example, very
little accumulation of mutations was seen in testes (44, 48), which contain highly
proliferating cells (57). In contrast, in liver and heart, which are slow or non-proliferating
tissues (57), there was a significant accumulation of mutations with age (43-46). These
data suggest that in addition to cell proliferation, other factors may also have a large
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impact on the accumulation of mutant cells with age. We hypothesize that the ability of
mutant cells to persist and clonally expand within a tissue may have the greatest impact
on the burden of mutant cell frequency with age.
Age is a risk factor for many diseases, including cancer (58). Similar to aging, the
accumulation of multiple mutations within cells is believed to cause cancer (59).
Furthermore, the clonal expansion of mutant cells has been shown to be a key step in
tumor formation. In fact, analysis of tumors shows that key mutations in tumor
suppressors and oncogenes are often shared by most, if not all, malignant cells within the
tumor (60-62). Because most mouse models for measuring mutations generally require
tissue disaggregation, information regarding clonal expansion cannot be gathered. For
example, if the same mutation is observed in multiple cells, it cannot be determined if the
mutation results from multiple independent events (e.g., at a mutation hot spot) or clonal
expansion. Thus, many of the studies analyzing the accumulation of mutant cells with age
either do not differentiate between the contribution of independent mutation events and
clonal expansion (45, 46, 48, 63) or completely remove the contribution of clonal
expansion by specifically analyzing only independent mutation events (42, 43). Our
previous studies (50) combined with the results here indicate that clonal expansion
contributes significantly to the overall increase in recombinant pancreatic cells with age.
For example, we observe that in the pancreas at -60% of the recombinant cells that
accumulate with age are due to clonal expansion (Wiktor-Brown et al., in preparation).
Thus, analyzing clonal expansion is important for ascertaining the underlying
mechanisms that contribute to the increase in mutant cell frequency with age.
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In contrast to the pancreas, skin does not appear to accumulate recombinant cells
with age. Previously, we have shown that not only clonal expansion but also de novo
recombination events contribute to the increase in recombinant pancreatic cells with age
(50). Therefore, the lack of accumulation of recombinant cells in skin may result from an
absence of clonal expansion, an inability to undergo de novo HR events, or a short
persistence of recombinant cells. Here we find that primary fibroblasts from juvenile and
aged mice showed no difference in their ability to undergo HR in response to
spontaneous and exogenous DNA damage, suggesting that an inability to undergo de
novo HR events with age does not cause the lack of accumulation of recombinant skin
cells. These observations suggest that recombinant cells do not accumulate with age in
the skin because recombinant cells are either short lived or do not clonally expand.
The ability of a cell to persist or clonally expand is cell type dependent. Thus, in
order to analyze the contribution of clonal expansion and persistence, it is important to
know the cell types of recombinant cells. Within the pancreas, recombinant cells are
mostly likely acinar cells (50). Acinar cells are part of the exocrine pancreas and secrete
hydrolytic enzymes into the duodenum that aid in digestion. The secretory unit within the
exocrine pancreas is a grape-like structure called an acinus, which contains ten to forty
acinar cells that secrete enzymes into a system of epithelial ducts (64). Interestingly,
acinar cells may play an important role in tumor formation. Evidence suggests that acinar
to ductal transdifferentation can occur in vivo and in vitro, leading to the formation of
pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinoma (65-71). In the
adult pancreas, acinar cells exhibit extremely low levels of proliferation (-1% of cells are
in S phase (72)) and persist for long periods of time (the turnover time of mouse acinar
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cells is estimated to be -500 days (57)). Thus, the dramatic accumulation of recombinant
acinar cells with age is most likely caused by a combination of de novo recombinant
events, clonal expansion and long persistence of acinar cells within the tissue.
Within the skin, recombinant cells that are detected in our system are most likely
fibroblasts. Fibroblasts are located within the dermal skin layer and secrete extracellular
matrix components, such as collagen and elastin. In addition, fibroblasts appear to play a
critical role in both wound healing and epithelial tumorigenesis (73-75). In response to
skin injury, fibroblasts migrate to the site of the wound, initiate proliferation and secrete
extracellular matrix components critical for restoration of skin structure and strength (73).
In the adult skin, fibroblasts have a low proliferation rate (-1-2% (76)) and persist for
long periods of time (the turnover time of fibroblasts is estimated to be 120-160 days
(77)). Thus, both skin fibroblasts and pancreatic acinar cells exhibit low proliferation
rates. Although the longer turnover time for acinar cells compared to skin fibroblasts may
contribute to the differences in the accumulation of recombinant cells with age,
fibroblasts do persist for significant periods of time within the skin. Thus, since
fibroblasts are both able to undergo de novo recombination events and persist within the
skin, an absence of clonal expansion contributes significantly to the complete lack of
accumulation of recombinant cells in skin with age. One hypothesis resulting from this
finding is that if fibroblasts are forced to clonally expand, for example in response to
injury, there may be an accumulation of recombinant cells. Indeed, treatment of FYDR
mice with an acute dose of high radiation induces an increase in recombinant cell
frequency within FYDR skin (55).
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The effect of aging on a number of DNA repair pathways has been examined in
multiple studies. The efficiency and fidelity of some DNA repair pathways such as base
excision repair and NHEJ have been shown to decrease with age (3-6, 78, 79). Here, we
show that the rate of HR in primary fibroblasts does not change with age, at least for mice
up to 62 weeks of age. To note, the maximal lifespan of C57BL/6J mice is 110 ± 21
weeks (80); thus, a change in HR may be seen in mice that are much older. Other studies
have determined the effect of aging on HR by measuring SCEs in young and aged
fibroblasts and lymphocytes. Interestingly, analyses of SCEs with age show conflicting
results, with some studies showing no change in the spontaneous frequency of SCEs with
age (81-83) and others indicating an increase in SCE frequency with age (84-86). Finally,
analysis of the male germline of Drosophila showed an increase in the frequency of HR
events with age (87). Thus, unlike some DNA repair pathways that exhibit decreased
repair capacity with age, the ability of cells to undergo HR does not decrease with age,
and, in fact, some studies suggest that the rate of HR may even be increased in aged cells.
HR is a critical DNA repair pathway known to contribute to aging. Here we have
demonstrated that the accumulation of recombinant cells with age is tissue-specific, with
pancreatic tissue showing a dramatic increase in recombinant cells and skin showing no
increase. The differences in recombinant cell accumulation with age are most likely due
to differences in the clonal expansion of recombinant cells within the tissues, indicating
that analysis of clonal expansion is critical for understanding overall mutation burden
within a tissue. Because of the ability to detect recombinant cells in vivo using
fluorescence, the FYDR mice provide a unique tool to study the contribution of clonal
expansion to recombinant cell frequency in multiple tissues. Thus, the effect of not only
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age but also genetics and environment on clonal expansion of recombinant cells can be
examined. Determining the relative importance of clonal expansion to mutant cell
frequency within different tissues may contribute to our understanding of mechanisms
that modulate susceptibility of various tissues to aged associated degeneration and cancer.
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Figure 5-1. FYDR system and analysis of pancreatic and skin cells by flow cytometry.
(A) Arrangement of the FYDR recombination substrate: large arrows indicate expression
cassettes; yellow boxes show coding sequences; black boxes show positions of deleted
sequences (deletion sizes not to scale). (B) Flow cytometry results of disaggregated skin
cells. Axes indicate relative fluorescence intensity at 515-545 nm (FLI) versus 562-588
nm (FL2). R2 region delineates EYFP-positive cells. Representative data are shown for a
negative control mouse, a positive control mouse, and a FYDR mouse. For clarity, data
for individual cells (dots) have been darkened in the FYDR R2 region. (C) Spontaneous
frequency of recombinant pancreatic (black bars) and skin (grey bars) cells per million
total cells analyzed as determined by flow cytometry for 100 FYDR mice aged 4-10
weeks. n, number of independent samples. (D) Average percentage of fluorescent
pancreatic (n=63) and skin (n=33) cells as determined by flow cytometry from 4-10 week
old positive control mice. Error bars indicate 1 standard deviation.
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Figure 5-2. Effects of aging on the frequency of recombinant cells and expression of the
FYDR substrate in the pancreas and skin. (A) Frequency of recombinant pancreatic cells
per million as determined by flow cytometry for juvenile (n=49) and aged (n=41) mice.
Previously, pancreata from a subset of juvenile and aged mice were analyzed (50). Here,
an additional 25 mice were added to each cohort. * Aged cohort is statistically
significantly higher than juvenile cohort (p<0.0001, Mann-Whitney). Medians are
indicated by black bars. Points on the x-axis indicate individual mice with 0 recombinant
cells. (B) Average percentage of fluorescent pancreatic cells as determined by flow
cytometry from juvenile (n=13) and aged (n=20) positive control mice. Error bars
indicate 1 standard deviation. (C) Frequency of recombinant skin cells per million as
determined by flow cytometry for juvenile (n=47) and aged (n=44) mice. Medians are
indicated by black bars. Points on the x-axis indicate individual mice with 0 recombinant
cells. (D) Average percentage of fluorescent skin cells as determined by flow cytometry
from juvenile (n=17) and aged (n= 11) positive control mice. Error bars indicate 1
standard deviation.
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Figure 5-3. Effects of aging on spontaneous levels of HR and DNA damage in primary
fibroblasts in vitro. (A) Frequency of recombinant cells per million at the time of initial
plating (black bars) and after -7 population doublings in culture (grey bars) of primary
fibroblasts from juvenile and aged mice as determined by flow cytometry. Error bars
indicate 1 standard deviation. (B) Average rate of HR in juvenile and aged cells as
determined by the method ofpo (52, 53). Error bars indicate 1 standard deviation. (C)
Example metaphase spread. Arrows indicate SCEs. (D) SCEs per chromosome in
juvenile (n=138) and aged (n=138) cells. Medians are indicated by black bars. (E)
Average olive tail moment and (F) Average percent tail DNA in juvenile (n=198) and
aged (n=198) cells. Error bars indicate 1 standard deviation.
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Figure 5-4. Effects of aging on spontaneous MMC induced HR in primary fibroblasts in
vitro. (A) Average cell density per million for mock- (black bars) and MMC-treated (grey
bars) primary fibroblasts from juvenile and aged mice. Error bars indicate 1 standard
deviation. (B) Average frequency of recombinant cell per million for mock- (black bars)
and MMC-treated (grey bars) primary fibroblasts from juvenile and aged mice. Error bars
indicate 1 standard deviation. Numbers represent average difference between MMC- and
mock-treated recombinant cell frequencies.
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Chapter VI
Loss of p53 Does Not Affect the Frequency or Rate of
Homologous Recombination in vivo
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Chapter 6
6.1 Abstract
The tumor suppressor p53 is transcription factor whose function is critical for
maintaining genomic stability in mammalian cells. In response to DNA damage, p53
initiates a signaling cascade that results in cell cycle arrest, DNA repair or, if the damage
is too severe, programmed cell death. In addition, p53 directly modulates the repair of
DNA by interacting with a number of DNA repair proteins, including those involved in
homologous recombination. Mitotic homologous recombination (HR) plays an essential
role in the repair of particularly deleterious DNA lesions, such as double-strand breaks
(DSBs) and broken replication forks. Loss of function of either p53 or HR leads to an
increased risk of cancer. Given the importance of both p53 and HR in maintaining
genomic integrity, we analyzed the effect of p53 on HR in vivo using Fluorescent Yellow
Direct Repeat (FYDR) mice. FYDR mice carry a transgene in which an HR event yields
a fluorescent phenotype. Here we show that p53 status does not significantly affect
homologous recombination in adult pancreatic cells in vivo. Furthermore, in vitro studies
analyzing the effect of p53 on HR in primary fibroblasts show no statistically significant
difference in the spontaneous rate of HR in p53 wild-type versus null cells. Thus, our
results indicate that p53 status does not significantly affect the spontaneous frequency or
rate of HR in the pancreas or in cultured fibroblasts.
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6.2 Introduction
p53 is a transcription factor that plays an essential role in maintaining genomic
stability. Indeed, greater than half of all tumors have lost p53 function either by mutation
(1, 2) or epigenetic silencing (3-5). Inherited mutations in p53 cause Li Fraumeni
syndrome, a genetic disorder characterized by a high and early incidence of cancer (6, 7),
and transgenic mice carrying germline deletions in p53 develop tumors at an accelerated
rate compared to p53 heterozygous and wild-type mice (8). Together, these data indicate
that p53 is a key inhibitor of tumor formation, and loss of p53 function provides cells
with critical selective advantages required for tumor formation.
Normally, p53 serves as the mediator of cell cycle arrest and/or apoptosis in
response to genotoxic stress, such as DNA damage. Cellular DNA is constantly exposed
to a plethora of endogenous and exogenous agents that can damage DNA (9). Of the
DNA lesions that form, DNA double-strand breaks (DSBs) are considered to be among
the most cytotoxic and mutagenic, since a single unrepaired DSB can result in the
permanent loss of over 100 million base pairs of genetic information (10), and misjoining
of DSBs can lead to gross chromosomal rearrangements (11). Mitotic homologous
recombination (HR) provides a critical pathway for the accurate repair of potentially
cytotoxic or mutagenic DSBs. By using homologous DNA sequences present on the
sister chromatid or homologous chromosome as templates, HR can repair DSBs with
minimal loss of sequence information (12). In addition, HR provides the only pathway
for the accurate repair of DSBs that arise as a result of broken replication forks. Thus, HR
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is a critical pathway for preventing tumor-promoting sequence rearrangements that can
result from DSBs.
Similar to inherited mutation in p53, germline mutations in genes that modulate
HR are associated with an increased risk of cancer (11, 13-16). Although HR is generally
error free, since over 40% of the genome is comprised of repeated elements (17),
exchanges between misaligned sequences that lead to insertions, deletions, translocations,
and loss of heterozygosity (LOH) can occur. It is not surprising that inherited mutations
in proteins that increase the rate of HR (i.e., WRN (18), BLM (19)) are associated with an
increased risk of cancer (16). While too much HR can be problematic, too little HR can
also lead to genomic instability. In the absence of HR, DSBs at broken replication forks
cannot be accurately reinserted to restart the replication fork (12). Instead, DSBs from
independent replication forks can be misjoined, leading to large scale sequence
rearrangements. Indeed, germline mutations in proteins that result in a suppression of HR
(i.e., BRCA1 (20), BRCA2 (21), FANCC (22)) also lead to an increased risk of cancer
(23-25). Thus, maintaining the proper level of HR is critical for preventing tumor
formation.
Given the importance of both p53 and HR in maintaining genomic stability, a
number of studies have analyzed the effect of p53 status on the repair of DSBs by HR.
Some in vitro studies suggest that p53 suppresses HR (26-31), potentially by interacting
with and regulating the transcription of Rad51 (32), a protein essential for HR.
Interestingly, however, a number of studies contradict these findings with results showing
that p53 status has no effect on HR (33-35). In addition, studies measuring the effect of
p53 on HR in vivo also show conflicting results. For example, using pink-eyed unstable
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(pUn) mice, in which a HR event during embryonic development can give rise to black
spots on the gray fur and retinal epithelium of adult mice (36, 37), p53 has been found in
one study to have a suppressive effect (38) and in another to have no effect (39) on the
spontaneous frequency of HR events. For technical reasons, the assays used in previous
studies can only detect HR events that occur during embryogenesis or in cultured cells in
vitro. Thus, the effect of p53 on HR in adult tissues in vivo had not been previously
evaluated.
Here, we investigate the effects of p53 on the frequency of HR events in vivo. To
study recombination in vivo, we applied the Fluorescent Yellow Direct Repeat (FYDR)
mice, in which a HR event at an integrated transgene yields a fluorescent cell (40).
Analysis of pancreata from FYDRY/+;p53 +/+ and FYDRY/';p53 -/- mice shows that neither
the number of recombination events nor the frequency of recombinant cells is affected by
p53 status. Since we have shown in previous studies that HR is an active repair process
within adult pancreata of FYDR mice (41), these data indicate that p53 does not affect
HR in adult pancreatic cells in vivo. To determine if p53 status affects the rate of HR, we
analyzed primary fibroblasts from FYDR mice in vitro. Although we observed an
increase in the average spontaneous rate of HR in p53 /- fibroblasts, the difference was
not statistically significant. Taken together, studies of HR both in vivo and in vitro
indicate that p53 status does not significantly affect the spontaneous frequency or rate of
HR in the pancreas or in cultured fibroblasts.
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6. 3 Materials and Methods
Animals
FYDR (40) and p53 mice (8) were described previously. Positive control FYDR-
Recombined (FYDR-Rec) mice arose spontaneously from an HR event in a FYDR
parental gamete, and all cells carry the full-length EYFP coding sequence (42). 9 week
old FYDRY ';p53 ÷/ + and FYDRY ';p53-' / cohorts had equal ratios of males to females.
Flow Cytometry
Pancreatic cells were disaggregated as described previously (41). Almost all
samples were analyzed by flow cytometry after imaging (see below). Disaggregated
pancreatic cells were pelleted and resuspended in 350 p.l OptiMEM (Invitrogen), filtered
(35 Vim), and analyzed with a Becton Dickinson FACScan flow cytometer (excitation 488
nm, argon laser). Live cells were gated by using forward and side scatter. On average, -1
million cells were analyzed per sample for flow cytometry.
Imaging
Pancreatic cells were imaged as described previously (41). Briefly, nuclei were
stained with 50 gpg/ml Hoechst 33342 (Sigma). Whole pancreata were pressed between
glass slides separated by 0.5 mm spacers. Sequential images were collected in black and
white using a lx objective. The images were manually compiled to cover the entire
visible surface area. Filters included: visible light; UV (Ex:330-380 nm, Em:420 nm);
Red (Ex:540/25 nm, Em:605/55 nm); and EYFP (Ex:460-500 nm, Em:510-560 nm).
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Images were collected using a fixed aperture time. Foci were counted manually in
blinded samples. The area of compiled pancreata images was determined using Scion
Image Beta 4.02 Win (Scion Corporation) by manually tracing the pancreas edge.
Isolation of Ear Fibroblasts
Ears were isolated, minced, and incubated at 370 C in 4 mg/ml collagenase/dispase
(Roche Applied Sciences). After 1 hour, two volumes of fibroblast medium was added
[DMEM, 15% FBS, 100 units/ml penicillin, 100 pg/ml streptomycin, 5 pg/ml
amphotericin B (Sigma)]. After 24 hours at 370C and 5% CO2, cells were triturated,
filtered (70-pm mesh; Falcon), and seeded into dishes.
Calculation of Rate in Primary Fibroblasts
Primary ear fibroblasts were isolated from FYDRY/+;p53 +/+ and FYDRY/+;p53'
littermates and rate experiments were performed in parallel. For each rate experiment,
-104 cells were seeded into 24 independent cultures. Cultures were expanded and
analyzed by flow cytometry once the density reached -106 cells per well. The MSS
Maximum Likelihood Method was used to determine the rate of recombination per cell
division as described (43). Rate experiments were repeated with fibroblasts from different
pairs of mice 3 times for males and 4 times for females.
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6.4 Results
Effect of p53 Status on Spontaneous Frequency of Recombinant Pancreatic Cells
To study HR in vivo, we previously developed FYDR mice that carry a direct
repeat recombination substrate containing two differently mutated copies of the coding
sequence for enhanced yellow fluorescent protein (EYFP). An HR event can restore full
length EYFP coding sequence, thus yielding a fluorescent cell (Fig. 6-1A) (40). One
method for measuring the in vivo frequency of recombinant cells is to analyze
disaggregated tissue by flow cytometry (41). We compared fluorescence intensities in
disaggregated pancreata from negative control and positive control (FYDR-Recombined
(42)) mice and established a region (R2) that excludes negative control cells (Fig. 6-1B).
To determine the effect of p53 status on HR in vivo, we analyzed recombinant
cells in pancreata of 9 week old FYDRY/ ;p53+/' and FYDRY/+;p53' mice (8, 40).
Analysis of recombinant cell frequency by flow cytometry reveals the total fraction of
fluorescent recombinant cells within a pancreas regardless of whether they arise as a
result of independent recombination events or clonal expansion (41, 42). Comparison of
pancreata from FYDRY/ ;p53/ 1' and FYDRY' ;p53Y mice shows that the frequency of
recombinant cells varies among individual animals within each cohort (Fig. 6-1C).
However, the median frequency of recombinant pancreatic cells is not statistically
different between the two cohorts (Fig. 6-1C), suggesting that p53 does not affect the in
vivo spontaneous frequency of recombinant cells in FYDR pancreata.
Analysis of FYDR pancreata by flow cytometry requires tissue disaggregation;
thus, the contribution of clonal expansion versus independent HR events on recombinant
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cell frequency cannot be determined. To quantify independent recombinant events, we
have previously developed in situ imaging techniques that enable the direct detection of
recombinant foci within intact pancreata (41). Briefly, we compared fluorescence
intensities under an EYFP-specific filter for negative control (Fig. 6-1D, left) and positive
control pancreata (Fig. 1D, center), and established imaging conditions that specifically
detect EYFP expressing cells in FYDR pancreata (Fig. 6-1D, right). To quantify
recombinant foci, FYDR pancreata are uniformly compressed to a thickness of 0.5 mm
and composite images that cover one side of the pancreatic surface area are created (Fig.
6-1E).
Recombinant cells within pancreata of FYDR mice are most likely acinar cells
(41). In the pancreas, acinar cells are arranged into grape-like structures called acini,
which contain ten to forty acinar cells that secrete enzymes into a system of epithelial
ducts (44). Given the low levels of proliferation of pancreatic acinar cells (45) and the
low probability of acinar cell migration among acini in adult tissue, each recombinant
focus within FYDR pancreata is most likely an independent recombination event. Thus,
the effect of p53 status on the ability of pancreatic cells to undergo recombination events
can be quantified by analyzing recombinant foci using in situ imaging. While the number
of recombinant foci detected by in situ imaging varied among individual animals within
FYDRY/+;p53 ÷+ and FYDRY'+;p53 -'" cohorts (Fig. 6-1F), the median number of
recombinant foci is not statistically different between the two cohorts (Fig. 6-1F).
Additionally, because the sizes of pancreata vary among mice within each cohort (data
not shown), we analyzed the number of foci per unit surface area for both FYDRY/+;p53 +1+
and FYDRY/+;p53-/ mice, and found that the median frequencies of recombinant foci per
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cm 2 are not statistically different between the two cohorts (Fig. 6-1G). Since HR is an
active repair process in the adult pancreas (41, 42), these data suggest that p53 status does
not affect the ability of adult pancreatic cells to undergo HR in vivo.
Effect of p53 Status on Spontaneous Frequency of Recombinant Pancreatic Cells in
Males Versus Females
Differences in susceptibility to certain diseases such as cancer differ between
males and females. To determine if the effect of p53 status on HR is modulated by sex,
we compared the frequency of recombinant cells and number of recombinant foci in male
and female mice. For both male (Fig. 6-2A) and female (Fig. 6-2B) mice, a trend towards
an increase in the median recombinant cell frequency and foci number in FYDRY/ ;p53-'
compared to FYDRY/+;p53 ÷' + mice is observed. However, these differences are not
statistically significant, suggesting that sex does not modulate the effect of p53 status on
HR in FYDR pancreata.
Interestingly, for both FYDRY'+;p53 +/+ and FYDRY/+;p53 -/- mice, female FYDR
mice have overall higher frequencies of recombinant cells than male mice (compare Fig.
6-2A and 6-2B). Previous studies of positive control FYDR-Recombined mice show that
female mice have higher EYFP expression levels than male mice (42). Since positive
control mice express the EYFP coding sequence under an identical promoter and at the
same locus as the FYDR recombination substrate, it is likely that similar differences in
expression between males and females are present in pancreatic tissue of the FYDR mice
as well. Thus, the apparent higher frequencies of recombinant cells in female as
compared to male FYDRY/';p53 +/+ and FYDRY/+;p53 /- mice can at least partially be
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explained by differences in the level of EYFP expression. Together these data indicate
that p53 status does not affect HR in pancreatic cells of both male and female mice in
vivo.
Effect of p53 sStatus on HR in Primary Fibroblasts in vitro
With its critical role in the repair of broken replication forks, HR is used
preferentially during late S/G 2 phases of the cell cycle to repair DSBs (46). To explore
the effect of p53 status on the rate of HR in dividing cells, primary fibroblasts from
FYDRY/+;p53+1+ and FYDRY+ ;p53 - -mice were cultured in vitro. The average rate of HR
as determined using the MSS Maximum Likelihood Method (43) appears to be higher in
FYDRY/+;p53 -/ compared to FYDRY/+;p53 +/+ fibroblasts (Fig. 6-3A), although this
difference is not statistically significant. To determine if the effect of p53 status on the
rate of HR is modulated by sex, we compared the rates in female versus male
FYDRY/+;p53 /' + and FYDRY/+;p53-' fibroblasts separately. A trend towards increased
rates of HR are seen in FYDRY/÷;p53-/- compared to FYDRY/+;p53'+/ fibroblasts for both
sexes (Fig. 3B), although again these differences are not statistically significant.
To determine if differences in the EYFP expression levels exist, fibroblasts from
male and female positive control mice were cultured in parallel with rate experiments.
Results show that there is no significant difference in the levels of detectable EYFP
expression between sexes in vitro (data not shown), indicating that differences in EYFP
expression do not affect the apparent rates of HR in both female and male fibroblasts.
Together these data suggest that FYDRY'+;p53-/- cells may have a higher rate of HR
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compared to FYDR Y';p53 +1+, although the trend is not sufficient to render the results
statistically significant.
6.5 Discussion
p53 is the guardian of genomic integrity. Indeed, loss of p53 function results in an
early onset and increased frequency of many types of cancers (6-8). In response to DNA
damage, p53 is activated and by regulating gene transcription initiates a signal cascade
that results in either DNA repair or cell death. Initially, p53 promotes the repair of DNA
damage by inducing cell cycle arrest and activating DNA repair proteins. However, in the
presence of extensive DNA damage, p53 signals for the elimination of damaged cells
through apoptosis, senescence or differentiation (for review see (47)). Because of the
critical role p53 plays in preventing tumorigenesis, we set out to understand the
mechanisms through which loss of p53 promotes genomic instability in pancreatic cells
and fibroblasts.
Mitotic HR is an important pathway for the accurate repair of DNA DSBs.
Although HR is generally error-free, recombination between misaligned sequences can
result in tumor promoting sequence rearrangements. Thus, maintaining the proper level
of HR is critical for maintaining genomic integrity. A number of studies have shown an
interaction between p53 and proteins involved in HR including RPA (48), Rad51 (49, 50),
BLM and WRN (51-53). These reports suggest that p53 interaction inhibits the function
of HR proteins. However, using FYDR mice we show that p53 status has no effect on HR
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in vivo in pancreatic cells and in vitro in primary fibroblasts, supporting a model in which
loss of p53 function does not significantly alter the spontaneous activity of HR. Previous
studies analyzing HR in vivo using pun mice show conflicting results (38, 39). Using the
fur spot assay, an initial study determined that p53 had no effect on HR in vivo (39).
However, a later study using the more sensitive eye-spot assay showed that loss of p53
increased HR events and specifically HR events that occurred during early embryonic
development (38). Because clonal expansion of recombined cells is required to detect
spots on both fur and retinal epithelium, pun mice can only be used to detect
recombination events that occur during embryogenesis. In contrast, FYDR mice can be
used to detect recombination events that occur in adult tissues in vivo. Therefore, the
differences in the results between our studies and those done with the pU" mice suggest a
difference in the importance of p53 in modulating HR during embryogenesis versus adult
life. Specifically, p53 may be less important in suppressing HR in adult versus embryonic
tissues. In addition, the effect of p53 on HR may be cell type specific with retinal
epithelial cells being more sensitive to loss of p53 function than pancreatic cells or
fibroblasts.
In addition to its role in modulating HR, p53 has been shown to modulate many
proteins involved in other DNA repair pathways either through transcriptional regulation
or direct protein interaction (47). Since efficient and accurate DNA repair plays a critical
role in maintaining genomic stability, it is not surprising that loss of p53 function has
been shown to cause defects in a number of DNA repair pathways including nucleotide
excision repair (54) and base excision repair (55). In addition, p53-null cells show
increased levels of error-prone DNA repair pathways such as non-homologous end
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joining (56). Thus, the misregulation of DNA repair pathways in the absence of p53 may
contribute to genomic instability, even if no dramatic change in the baseline rate of HR is
present.
Germline mutations in p53 cause an increased frequency of tumor formation. Our
data suggests that the increased cancer incidence in p53 -'- mice may not be the result of
misregulation of HR since FYDRY/+;p53 /- mice do not shown an increase in recombinant
cells compared to their p53 wild-type littermates. The combination of flow cytometry and
in situ imaging can provide information regarding the importance of both de novo
recombination events and clonal expansion to the frequency of recombinant cells within
the pancreas. In addition to genetic conditions, the effect of environmental exposures on
HR can also be studied using FYDR mice (41, 42). Although p53 status does not appear
to affect the spontaneous frequency of HR, given the importance of p53 in responding to
DNA damage, treatment of FYDRY/+;p53 +' and FYDRY/+;p53 -/- mice or cells with
exogenous DNA damaging agents may result in a differential susceptibility to damage
induced recombination. Thus, FYDR mice provide a unique tool to study the individual
and combined effects of cancer risk factors, such as genetic conditions, environment
exposures and aging, on the repair of DSBs by HR in vivo.
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Figure 6-1. FYDR system and analysis of pancreatic cells by flow cytometry and in situ
imaging. (A) Arrangement of the FYDR recombination substrate: large arrows indicate
expression cassettes; yellow boxes show coding sequences; black boxes show positions
of deleted sequences (deletion sizes not to scale). (B) Flow cytometry results of
disaggregated skin cells. Images adapted from Wiktor-Brown, et al (41). Axes indicate
relative fluorescence intensity at 515-545 nm (FL1) versus 562-588 nm (FL2). R2 region
delineates EYFP-positive cells. Representative data are shown for a negative control
mouse, a positive control mouse, and a FYDR mouse. For clarity, data for individual cells
(dots) have been darkened in the FYDR R2 region. (C) Spontaneous frequency of
recombinant pancreatic cells per million as determined by flow cytometry for
FYDRY"+;p53 +/+ (n=48) and FYDRY/+;p53' (n=47) mice. Medians are indicated by black
bars. Points on the x-axis indicate individual mice with 0 recombinant cells. (D) Analysis
of fluorescent foci in mouse pancreata. Images adapted from Wiktor-Brown, et al (41).
For analysis of freshly excised tissue, images show overlays of EYFP- (510-560 nm) and
UV- (420 nm) filtered images. Nuclei are stained with Hoechst 33342. Portions of
negative control (left), positive control (middle) and FYDR (right) mouse pancreata
imaged at lx (scale bar, 1 mm). Brightness and contrast for UV-filtered images were
adjusted equivalently. For EYFP images, brightness and contrast for negative control and
FYDR (5-s exposure) images were adjusted equivalently. To avoid overexposure of the
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positive control, a shorter exposure time was used (1 s) and brightness and contrast were
not adjusted. (E) Compiled image for representative FYDR pancreata. Image was
collected at lx (bar, 1 cm) using an EYFP filter (510-560 nm). The edge of the pancreatic
tissue is outlined. (E) Spontaneous recombinant foci per pancreas detected by in situ
image analysis for FYDRY/';p53 ÷' (n=49) and FYDRY/';p53-' (n=47) mice. Medians are
indicated by black bars. (F) Spontaneous recombinant foci per cm2 detected by in situ
image analysis for FYDRY/';p53 ÷' (n=49) and FYDRY/';p53-' (n=47) mice. Medians are
indicated by black bars.
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Figure 6-2. The effect of p53 status on HR in males versus female. (A) Male mice:
spontaneous frequency of recombinant pancreatic cells per million as determined by flow
cytometry (left, p=0.75, 2-tailed Mann-Whitney) and spontaneous recombinant foci per
pancreas detected by in situ image analysis (right, p=0.42, 2-tailed Mann-Whitney) for
FYDRY'+;p53+'+ (n=25) and FYDRY/';p53 "- (n=27) mice. (B) Female mice: spontaneous
frequency of recombinant pancreatic cells per million as determined by flow cytometry
(left, p=0.45, 2-tailed Mann-Whitney) and spontaneous recombinant foci per pancreas
detected by in situ image analysis (right, p=0.48, 2-tailed Mann-Whitney) for
FYDRY ';p53' (n=24) and FYDRY ';p53' (n=20) mice. Medians are indicated by black
bars. Points on the x-axis indicate individual mice with 0 recombinant cells.
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Figure 6-3. Effects of p53 status on spontaneous levels of HR as determined by the
method ofpo (43, 57). (A) Average rate of HR in FYDRY' ;p534 1 (n=7) and
FYDRY/';p53 - (n=7) primary fibroblasts (p=0.16, 2-tailed Student's t test). Error bars
indicate 1 standard deviation. (B) Average rate of HR in FYDRY/';p53 ÷/ ÷ (black bars) and
FYDRY'+;p53" (grey bars) primary fibroblasts from male (p=0.56, 2-tailed Student's t
test) and female (p=0.14, 2-tailed Student's t test). Error bars indicate 1 standard
deviation.
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With its essential role in the repair of double-strand breaks and broken replication
forks, homologous recombination is an important modulator of genomic stability.
Deregulation of homologous recombination, whether up or down, can lead to an
increased risk of cancer. Here we have used Fluorescent Yellow Direct Repeat mice
(FYDR) to explore the effects of certain cancer risk factors, such as age, exposure to
exogenous DNA damaging agents, and p53 status on homologous recombination in vivo.
Given that homologous recombination appears to play an important role in
increasing the risk of pancreatic cancer, we examined homologous recombination in
pancreatic tissue of FYDR mice in vivo. We developed techniques to analyze
recombinant cells both by flow cytometry of disaggregated tissue and by in situ imaging
of intact pancreata. We first applied these techniques to determine if homologous
recombination is an active repair process in the pancreas. Treatment of FYDR mice with
the DNA damaging agent mitomycin-C or cisplatin (see Appendix I) shows an induction
in both the frequency of recombinant cells and number of recombinant foci, indicating
that homologous recombination is indeed an active repair process in adult pancreatic cells
and that exposure to exogenous DNA damaging agents can induce recombination in the
pancreas. Furthermore, we determined that in situ imaging is a more sensitive method
than flow cytometry for detecting exposure-induced recombinant cells, yielding statistical
significance with smaller cohorts. Thus, in situ imaging and flow cytometry can be used
in combination to provide information about both independent recombination events and
overall recombinant cell frequency.
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Analysis of FYDR pancreata by both in situ imaging and flow cytometry revealed
a large variation in recombinant pancreatic cell frequency among mice. While some of
this variation may be due to differences in homologous recombination, the expression of
the FYDR transgene may also contribute to inter-mouse variation in recombinant cell
frequencies. To explore inter-mouse variation, we exploited positive control FYDR-
Recombined mice. Our data showed that while there is variation in enhanced yellow
fluorescent protein (EYFP) expression within male and female cohorts, on average
females exhibit higher EYFP expression than males. Thus, we concluded that when
comparing recombinant cell frequencies among different conditions equal ratios of males
to females must be used. In addition, since expression of the FYDR transgene can affect
the apparent frequency of recombinant cells, a cohort of positive control mice must be
included in all experiments to determine the effect of any condition on EYFP expression.
The development of methods to detect recombinant pancreatic cells and the
understanding of their constraints when analyzing homologous recombination enabled
the application of these techniques to study the effect of additional cancer risk factors on
homologous recombination in the pancreas. Given the importance of age as a risk factor
for pancreatic cancer, we analyzed the changes in the frequency of recombinant cells and
number of recombinant foci in pancreata of FYDR mice. We observed a dramatic
accumulation of recombinant cells with age, including an -23-fold increase in the
frequency of recombinant cells and an -9-fold increase in the number of recombinant foci
per cm , suggesting that both de novo recombination events and clonal expansion
contribute to the overall increase in the recombinant cell frequency with age. To further
analyze the effect of clonal expansion on the accumulation of recombinant cells with age,
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the laboratory of Peter T. So developed a two-photon imaging technique to quantify the
number of cells per recombinant focus. Using two-photon imaging, we showed that the
median number of cells per recombinant focus increased from two to six in juvenile and
aged mice, respectively, indicating that recombinant cells can clonally expand with age.
The relative contribution of clonal expansion to the increase in recombinant cell
frequency with age can be determined by analyzing the importance of de novo
recombination events to the increase in recombinant cell frequency. The estimate of the
contribution of clonal expansion to total recombinant cell number depends greatly on the
total number of cells within the pancreas. Taga et al determined that a 4 week old mouse
pancreas has -27 million cells. In our studies, we have found that the mouse pancreas
doubles in size from 4 weeks to 1 year; however, we do not know if this doubling in
pancreas weight is due to a doubling in the number of pancreatic parenchymal cells, an
increase in other cell types such as fibroblasts, inflammatory cells, adipocytes, a change
in the concentration of extra cellular matrix components or a combination of these. If we
assume no age-dependent increase in parenchymal pancreatic cells, we can calculate the
minimum contribution of clonal expansion to recombinant cell accumulation with age.
The frequency of recombinant cells was ~1/106 and -30/106 in juvenile and aged
mice, respectively. Given that a pancreas contains -27 million cells, we can calculate that
juvenile mice have -27 recombinant cells per pancreas and aged mice have -810. A
similar calculation can be made for the total number of recombinant foci per pancreas. If
we assume that we are able to detect -1/3 of all recombinant foci for both juvenile and
aged mice, then we estimate that juvenile and aged mice have -18 and -282 recombinant
foci per pancreas, respectively. Given that -352 new recombination events and -783 new
187
recombinant cells appear as the mice age, then -60% of the increase in the number of
recombinant cells with age is due to clonal expansion. Independently, we analyzed 68
recombinant foci from aged mice using two-photon microscopy and determined that the
total number of recombinant cells contained within all foci was 898. Since 68 of these
898 recombinant cells were due to de novo recombination events, then -90% of the
increase in recombinant cells with age is due to clonal expansion. Together these data
show that clonal expansion contributes -60-90% of the overall increase in the number of
pancreatic cells harboring DNA sequence rearrangements with age.
In addition to examining homologous recombination in pancreatic cells, we
carried out similar analyses for skin tissue. Comparison of spontaneous recombinant cell
frequencies in pancreatic and skin tissues from young FYDR mice shows that pancreatic
tissue often contains more recombinant cells. This higher frequency of recombinant
pancreatic compared to skin cells cannot be explained by expression of the FYDR
transgene alone, suggesting that fluorescent recombinant cells within the pancreas may be
more likely to clonally expand than those contained within the skin. The difference in
recombinant cell frequency between pancreatic and skin tissues is further increased with
age, as pancreatic tissue shows a dramatic accumulation of recombinant cell frequency
and skin shows no accumulation. In vitro analyses of the rate of homologous
recombination, spontaneous levels of DNA damage, and damage-induced recombinant
cell frequency in juvenile versus aged primary fibroblasts show that homologous
recombination is not suppressed with age, suggesting that the lack of accumulation of
recombinant cells in the skin is most likely not due to an inability to undergo de novo
homologous recombination events. Since we have shown that the accumulation of
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recombinant cells in aged pancreata results from both de novo recombination events and
clonal expansion of existing recombinant cells, the lack of accumulation of recombinant
is most likely due to the absence of extensive clonal expansion in skin fibroblasts with
age.
Finally, in addition to age and exposure to exogenous agents, genetic conditions
can also affect susceptibility to cancer. Here we analyzed the effect of the key modulator
of genomic stability, p53, on homologous recombination in FYDR mice. Results indicate
that p53 status does not significantly affect the spontaneous frequency of recombinant
cells in the pancreas in vivo or the spontaneous rate of homologous recombination in
cultured fibroblasts in vitro. However, given the importance of p53 in responding to
DNA damage, treatment of FYDRY+ ;p53+'+ and FYDRY"+;p53- mice or cells with
exogenous DNA damaging agents may result in a differential susceptibility to damage
induced recombination.
In this work, we have shown that FYDR mice provide a powerful tool for
studying the effects of age, environmental exposure and genetic conditions on
homologous recombination in vivo. These are the first series of studies to analyze
homologous recombination in pancreatic cells and the first to demonstrate the significant
contribution of clonal expansion to the accumulation of recombinant cells with age. The
assays that we have developed to measure the frequency of recombinant cells, the number
of independent recombination events and the contribution of clonal expansion can be
applied to explore how additional genetic and environmental risk factors modulate
double-strand break formation and repair by homologous recombination.
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Because the accumulation of recombinant cells can be monitored over months and
even years, long-term effects of both acute and chronic exposures relevant to cancer can
also be studied. Although we see an accumulation of recombinant pancreatic cells with
age, an important risk factor for pancreatic cancer, the effect of neoplastic transformation
on homologous recombination in the pancreas is not yet known. Currently, FYDR mice
are being crossed with mice that are predisposed to pancreatic intraepithelial neoplasias.
The changes in the frequency of recombinant cells and the number of recombinant foci
with cellular transformation can be assessed to determine if changes in the number of
cells harboring DNA sequence are seen with progressive stages of cancer. In addition,
since chronic infection is a risk factor for many types of cancer, FYDR mice are also
being infected with gastro-intestinal bacteria to determine the effect of chronic
inflammation on homologous recombination in pancreatic cells. Finally, FYDR mice can
also be used to determine the combined effects of multiple risk factors on tumor
formation in vivo.
In addition to analyzing the effects of cancer risk factors on homologous
recombination pancreas and skin, this work can be extended to other tissues. We have
shown using positive control FYDR-Rec mice that in addition to pancreas and skin,
homologous recombination in kidney, lung, and other tissues can potentially be studied
using FYDR mice. Similar techniques to the ones described here can be developed to
measure independent recombination events, overall recombinant cell frequency and
clonal expansion in other tissues. Thus, the FYDR mice can be used to elucidate the role
of double-strand break formation and repair by homologous recombination in tumor
formation for multiple tissues.
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Appendix I
Cisplatin Treatment Induces Homologous Recombination in
Adult Pancreatic Cells in vivo
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A1.1 Introduction
Mitotic homologous recombination is critical for repairing double-strand breaks
and interstrand cross-links. In addition, homologous recombination provides the only
pathway for the accurate repair of double-strand ends that arise when a replication fork is
broken upon encounter with a blocking DNA lesion or a single strand gap (1-5). If not
repaired properly, DNA double-strand breaks and replication fork-associated double
strand ends can lead to tumor-promoting DNA sequence rearrangements (6).
Ironically, although DNA damage that inhibits replication can induce tumorigenic
sequence rearrangements, many agents used to treat cancer are in fact DNA damaging-
agents that inhibit replication fork progression. Thus many chemotherapeutic agents are
highly recombinogenic (7-12). Interestingly, elevated levels of homologous
recombination proteins within tumor cells are associated with an increased resistance to
many cancer chemotherapeutics (13-18) and a poor prognosis for cancer survival (19). In
contrast, cancer cells deficient in homologous recombination (e.g., breast tumors with
BRCA2 mutations (20, 21)) are rendered sensitive to chemotherapeutic agents that induce
replication fork breakdown (22-25). Therefore, knowledge about the effect of a cancer
chemotherapeutic on homologous recombination in vivo and the homologous
recombination capacity of cells is critical for designing effective cancer treatments for
different tumors.
Cisplatin is a common cancer chemotherapeutic that is used to treat many types of
cancers including small cell lung, testicular, bladder, ovarian, head and neck and others.
Depending on the type and stage of cancer, cisplatin is given in various doses ranging
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from 20 to 100 mg/m2, and usually in conjunction with other chemotherapeutic agents
(26-30). For mice, the LD50 of cisplatin is estimated to be -8.0 mg/kg for a single
intraperitoneal injection (31), which would be an equivalent dose of --309 mg/m2 for a
150 lb human.
A1.2 Materials and Meth6ds
Animals
C57BL/6 Fluorescent Yellow Direct Repeat (FYDR) mice have been described
previously (32). Positive control FYDR-Recombined (FYDR-Rec) mice arose
spontaneously from an HR event in a FYDR parental gamete, and all cells carry the full-
length EYFP coding sequence (33). Cisplatin- and mock-treated FYDR cohorts had equal
ratios of males to females.
Cisplatin Treatment
Cisplatin (cis-Diamminedichloroplatinum(II), Sigma) was prepared fresh daily.
To determine the molar concentration of cisplatin solution, the absorbance of the cisplatin
solution at 300 nm was divided by the extinction coefficient (131). For treatment of mice,
the cisplatin concentration was adjusted to 0.5 mg/ml. Five- to 6-week old mice were IP
injected with 5 mg/kg of body weight of 0.5 mg/ml cisplatin. Mock-treated controls were
injected with equal volumes of PBS. Mice were analyzed 3.5 weeks after injection.
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Flow Cytometry
Pancreatic cells were disaggregated as described previously (34). Almost all
samples were analyzed by flow cytometry after imaging (see below). Disaggregated
pancreatic cells were pelleted and resuspended in 350 .l OptiMEM (Invitrogen), filtered
(35 pm), and analyzed with a Becton Dickinson FACScan flow cytometer (excitation 488
nm, argon laser). Live cells were gated by using forward and side scatter. On average, -1
million cells were analyzed per sample for flow cytometry.
Imaging
Pancreatic cells were imaged as described previously (34). Briefly, nuclei were
stained with 50 gpg/ml Hoechst 33342 (Sigma). Whole pancreata were pressed between
glass slides separated by 0.5 mm spacers. Sequential images were collected in black and
white using a lx objective. The images were manually compiled to cover the entire
visible surface area. Filters included: visible light; UV (Ex:330-380 nm, Em:420 nm);
Red (Ex:540/25 nm, Em:605/55 nm); and EYFP (Ex:460-500 nm, Em:510-560 nm).
Images were collected using a fixed aperture time. Foci were counted manually in
blinded samples. The area of compiled pancreata images was determined using Scion
Image Beta 4.02 Win (Scion Corporation) by manually tracing the pancreas edge.
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A1.3 Results
To determine the effect of cisplatin treatment on homologous recombination in
pancreatic cells in vivo, 5- to 6-week-old FYDR mice were injected with cisplatin. The
median frequencies of recombinant cells by flow cytometry (Fig. Al-1A) and of
recombinant foci by in situ imaging (Fig. Al-1B) were higher among the cisplatin-treated
mice, indicating that cisplatin induces homologous recombination events in vivo.
However, cisplatin induction is statistically significant only when analyzed by in situ
imaging, suggesting that although both flow cytometry and in situ imaging detect
recombinant cells, in situ imaging may be a more sensitive method for detecting
exposure-induced recombinant cells.
It is formally possible that the increased frequency of recombinant cells after
cisplatin treatment is because of increased EYFP expression. To explore this possibility,
we exploited positive control animals in which all cells carry the recombined substrate
(full-length EYFP). Flow cytometry of pancreatic cells from mock- and cisplatin-treated
positive control mice revealed that there was no statistically significant difference in
EYFP expression between the cohorts (Figure AI-1C). Thus, we conclude that
differences in EYFP expression do not affect the apparent frequencies of recombinant
cells in cisplatin- and mock-treated mice, indicating that the increase in recombinant cell
frequency after cisplatin treatment is the result of an induction of recombinant cells.
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A1.4 Conclusions
The majority of cisplatin-induced lesions are intra-strand crosslinks (35), which
are predominantly repaired by nucleotide excision repair (for review see (36)). However,
if these lesions persist until replication, they can cause replication fork breakdown and
the formation of a double-strand end, which can only be accurately repaired by
homologous recombination (37). Treatment of mice with a dose of 5 mg/kg of body
weight cisplatin is equivalent to -~190 mg/m2 for a 150 lb human, which is -2-fold higher
than the highest single cisplatin dose (100 mg/m2) given to patients during chemotherapy.
However, since most chemotherapeutic regiments require multiple treatments, the total
dose a patient receives may be higher than that give to the mice in this study.
The data presented here show that cisplatin is a potent recombinogen in adult
pancreatic cells in vivo, inducing an -4-fold increase in the frequency of recombinant
cells and an -3-fold increase in the number of recombinant foci. Thus, homologous
recombination is an active repair pathway in adult pancreatic cells in vivo and is activated
in response to cispatin-induced DNA lesions.
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Figure Al-1. Cisplatin-induced homologous recombination in mouse pancreata. Medians
are indicated by black bars. Points on the x axis indicate individual mice with zero
recombinant cells. (A) Frequency of recombinant cells per million as determined by flow
cytometry for mock-treated (n = 25) and cisplatin-treated (n = 25) FYDR mice (p = 0.09).
(B) Recombinant foci per pancreas detected by in situ image analysis for mock-treated (n
= 25) and cisplatin-treated (n = 25) FYDR mice. * Cisplatin-treated cohort is statistically
significantly higher than mock-treated cohort (p = 0.008). (C) Average percentage of
fluorescent pancreatic cells as determined by flow cytometry from mock- (n = 16) and
cisplatin-treated (n = 17) positive control mice (ratio of males to females is the same in
mock- and cisplatin-treated cohorts). Error bars indicate 1 standard deviation.
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Appendix II
Comparing the Levels of mRNA and Protein Expression in
Positive Control FYDR-Recombined Mice
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A2.1 Introduction
The Fluorescent Yellow Direct Repeat (FYDR) mice carry a direct repeat
recombination substrate in which a homologous recombination event can restore full-
length enhanced yellow fluorescent protein (EYFP) coding sequence. The FYDR
recombination substrate is integrated into chromosome 1 of the mouse genome in a
region with no known genes (1). In the course of analyzing recombinant cells in
pancreata of FYDR mice, we noticed a large variation in both the frequency of
recombinant cells and the number of recombinant foci among mice. Although this inter-
mouse variation in recombinant pancreatic cells may be the result of differences in
homologous recombination, it is also possible that this variation results from differences
in the ability to detect fluorescent cells (e.g., differences in expression levels of EYFP
from the FYDR transgene). For example, if EYFP is expressed at lower levels from the
FYDR transgene, it will be more difficult to detect recombinant cells. Therefore, in order
to study the effect of cancer risk factors on homologous recombination in the pancreas,
the effect of those factors on expression of the FYDR transgene must also be determined.
One potential method for determining the level of FYDR transgene expression is
to measure mRNA levels of the FYDR transgene. However, levels of mRNA transcript
do not necessarily correlate with protein levels (2), and in our studies we are detecting
EYFP protein expression after a recombination event in FYDR mice. In order to
determine if there is a correlation between FYDR transgene mRNA levels and EYFP
protein levels, we utilized positive control FYDR-Recombined mice. FYDR-Recombined
mice arose spontaneously from a homologous recombination event in a FYDR parental
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gamete. Thus, all cells in FYDR- Recombined mice carry the full-length EYFP coding
sequence under the identical promoter and locus as the FYDR mice and have the
potential to express EYFP. Because the FYDR- Recombined mice are the perfect positive
control for FYDR transgene expression, they can be used to determine if FYDR
transgene mRNA levels correlate with EYFP protein expression.
A2.2 Materials and Methods
Flow Cytometry
Pancreatic cells were disaggregated as described previously (3). Disaggregated
pancreatic cells were pelleted and resuspended in 400 gl OptiMEM (Invitrogen) and
filtered (35 pm). 100 pl of cell suspension post-filtration was removed for RT-PCR
analysis. Remaining cell suspension (300 pl) was analyzed with a Becton Dickinson
FACScan flow cytometer (excitation 488 nm, argon laser). Live cells were gated by using
forward and side scatter.
RT-PCR
Pancreatic cells from the 100 pl sample removed for RT-PCR analysis were
pelleted for 5 minutes in microcentrifuge at 3000 rpm, supernatant was removed and cells
were immediately frozen in liquid nitrogen and stored at -800C. Following RNA
extraction using the RNeasy® Mini Kit animal cell isolation protocol (Quiagen), RNA
concentration was determined by measuring absorbance at 260 nm. Following DNase I
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(Invitrogen) digestion treatment, reverse transcription was performed using Superscript TM
III First Strand Synthesis System (Invitrogen), and cDNA concentration was determined
by measuring absorbance at 260 nm. RT-PCR was performed using SYBR Green PCR
Kit (Quiagen) for GAPDH and FYDR genes with annealing temperatures of 60.50 C and
70 0 C, respectively. Primers: GAPDHfor: ACTGGCATGGCCTTCCG; GAPDHrev: CA
GGCGGCACGTCAGATC; FYDRfor: AAGTTCATCTGCACCACCGGCAAGCTG;
FYDRrev: TCGTGCTGCTTCATGTGGTCGGGGTAG. For each PCR run, samples
including standers were run in triplicate. Quantification was based on standard curves
made from serial dilutions of one sample, and average ratio of FYDR to GAPDH
transcript was calculated for each sample.
A2.3 Results
To determine the correlation between FYDR transgene mRNA levels and EYFP
protein expression, mRNA levels were measured using RT-PCR analysis, and EYFP
protein expression was analyzed by flow cytometry. A fairly good correlation (R2 = 0.47)
between EYFP protein level and FYDR transgene mRNA level was observed (Figure A2-
1), suggesting that FYDR transgene levels can be used to approximate expression of
EYFP protein in FYDR- Recombined mice.
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A2.4 Conclusions
Because in positive control mice the EYFP coding sequence is expressed under an
identical promoter and at the same locus as the FYDR recombination substrate, it is likely
that differences in expression of the FYDR transgene in FYDR- Recombined mice are
also present in FYDR mice. Thus, the correlation between FYDR transgene mRNA level
and EYFP protein expression observed for FYDR- Recombined pancreatic cells is most
likely similar in FYDR pancreatic cells. Currently, in order to determine the effect of a
genetic condition or environmental exposure on FYDR transgene expression, a cohort of
FYDR- Recombined mice is included in all studies. However, given the correlation
between FYDR transgene mRNA levels and EYFP protein expression, samples can
instead be taken from disaggregated pancreata of FYDR mice for each study condition.
RT-PCR analysis can be performed to compare FYDR transgene mRNA levels to
determine if any apparent differences in the frequency of recombinant cells is due to
differences in homologous recombination or differences in expression.
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Appendix III
Analysis of the Fraction of Recombinant Cells that can be
Detected by In Situ Imaging on Both Sides of a Compressed
Pancreatic Sample
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A3.1 Introduction
To study homologous recombination in pancreata of Fluorescent Yellow Direct
Repeat (FYDR) mice, an in situ imaging method was developed for detecting
recombinant foci on the surface of intact pancreatic tissue (1). Briefly, pancreata are
uniformly compressed to a thickness of 0.5 mm, and composite images that cover one
side of the pancreatic surface area are created. Given the thickness of the pancreatic
sample, all foci contained within the pancreas may not be detectable on the surface of the
pancreas. In addition, recombinant foci within pancreatic samples may not be evenly
distributed such that imaging only one side of the pancreas may not be representative of
the recombinant foci contained within the entire pancreas.
A3.2 Results and Conclusions
To determine the percentage of recombinant foci that can be detected on both
sides of a compressed pancreas and to determine the difference in the number of
recombinant foci on the two sides of a compressed pancreas, composite images were
taken of both sides of FYDR pancreata for five mice. Recombinant foci were manually
counted on images of both sides of a pancreas. A comparison of the locations of foci on
both sides was made to determine which foci could be seen on both sides of the pancreas.
The results for the number of recombinant foci per pancreas side are shown in Table A3-
1. Similar numbers of recombinant foci were detected on both sides of each pancreatic
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sample. In addition, although the number of recombinant foci that could be detected on
both sides of a pancreas varied, on average -28% of foci could be detected on both sides
of the pancreas sample. Together, these data indicate that analysis of one side of a
pancreatic sample provides representative data for the number of recombinant foci
located within the entire pancreas.
Table A3-1. Comparison of recombinant foci seen on two sides of a FYDR pancreas
sample prepared for in situ imaging
Number of Number of foci
foci Side 2 common to both sides
17 3
44 14
7 3
16 2
39 9
Total average
Average percentage
of foci seen
16.0
26.2
58.9
13.9
23.4
27.7
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Sample
number
1
2
3
4
5
Number of
foci Side 1
21
68
4
13
38
A3.3
1.
